

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/005527 A1

(51) International Patent Classification⁷: **C12P 13/04**,
C12N 9/02, 9/10, 9/88, 1/20, 15/10, C07H 21/04

(74) Agents: **HANLEY, Elizabeth, A.** et al.; Lahive & Cock-
field, LLP, 28 State Street, Boston, MA 02109 (US).

(21) International Application Number:
PCT/US2002/021336

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (*for all designated States except US*): **BASF**
AKTIENGESELLSCHAFT [DE/DE]; 67056 Lud-
wigshafen (DE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **YOCUM, R.**,
Rogers [US/US]; 4 Orchard Lane, Lexington, MA 02420
(US). **PATTERSON, Thomas, A.** [US/US]; 89 Church
Street, Attleboro, MA 02760 (US). **PERO, Janice, G.**
[US/US]; 20 Solomon Pierce Road, Lexington, MA 02420
(US). **HERMANN, Theron** [US/US]; 18 Chilhowie
Drive, Kinnelon, NJ 07405 (US).

Published:

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

(57) Abstract: The present invention features improved methods for the enhanced production of pantoate and pantothenate utiliz-
ing microorganisms having modified pantothenate biosynthetic enzyme activities and having modified methylenetetrahydrofolate
(MTF) biosynthetic enzyme activities. In particular, the invention features methods for enhancing production of desired products
by increasing levels of a key intermediate, ketopantoate, by increasing enzymes or substrates that contribute directly or indirectly
to its synthesis. Recombinant microorganisms and conditions for culturing same are also featured. Also featured are compositions
produced by such microorganisms.



WO 2004/005527 A1

MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

Related Applications

5 This application is related to International Patent Application No. PCT/US02/00925, entitled "Microorganisms and Processes for Enhanced Production of Pantothenate", filed January 18, 2002 (pending), and to International Patent Application No. PCT/US00/25993, entitled "Methods and Microorganisms for Production of Panto-
10 Compounds", filed September 21, 2000 (expired). The entire content of the above-referenced applications is incorporated herein by this reference.

Background of the Invention

 Pantothenate, also known as pantothenic acid or vitamin B5, is a member of the B complex of vitamins and is a nutritional requirement for mammals, including
15 livestock and humans (*e.g.*, from food sources, as a water soluble vitamin supplement or as a feed additive). In cells, pantothenate is used primarily for the biosynthesis of coenzyme A (CoA) and acyl carrier protein (ACP). These coenzymes function in the metabolism of acyl moieties which form thioesters with the sulfhydryl group of the 4'-
20 phosphopantetheine portion of these molecules. These coenzymes are essential in all cells, participating in over 100 different intermediary reactions in cellular metabolism.

 The conventional means of synthesizing pantothenate (in particular, the bioactive D isomer) is *via* chemical synthesis from bulk chemicals, a process which is hampered by excessive substrate cost as well as the requirement for optical resolution of racemic intermediates. Accordingly, researchers have recently looked to bacterial or
25 microbial systems that produce enzymes useful in pantothenate biosynthesis processes (as bacteria are themselves capable of synthesizing pantothenate). In particular, bioconversion processes have been evaluated as a means of favoring production of the preferred isomer of pantothenic acid. Moreover, methods of direct microbial synthesis have recently been examined as a means of facilitating D-pantothenate production.

30 There is still, however, significant need for improved pantothenate production processes, in particular, for microbial processes optimized to produce higher yields of desired product.

Summary of the Invention

35 The present invention relates to improved processes (*e.g.*, microbial syntheses) for the production of pantothenate. Pantothenate production processes have been described in related applications which feature, for example, microbes engineered to overexpress key enzymes of the pantothenate biosynthetic pathway and the

isoleucine-valine biosynthetic pathway (see *e.g.*, Figure 1). Strains have been engineered that are capable of producing > 50 g/l of pantothenate in standard fermentation processes (see *e.g.*, International Public. No. WO 01/21772 and U.S. Patent Application No. 60/262,995). In particular, increasing the expression of the *panB*, *panC*,
5 *panD* and *panE1* genes and increasing the expression of the *ilvBNC* and *ilvD* genes results in strains that convert glucose (pyruvate) to commercially attractive quantities of pantothenate.

In order to enhance production levels of for example, pantothenate, various improvements on the above-described methods have now been developed. For
10 example, U.S. Patent Application Serial No. 09/667,569 describes production strains having modified (*e.g.*, deleted or decreased-activity) pantothenate kinase enzymes. In such strains, the pantothenate levels are effectively increased by decreasing utilization of pantothenate for coenzymeA ("CoA") synthesis. U.S. Patent Application Serial No. 60/262,995 further describes improved pantothenate-production strains that have been
15 engineered to minimize utilization of various pantothenate biosynthetic enzymes and/or isoleucine-valine biosynthetic enzymes and/or their respective substrates from being used to produce an alternative product identified as [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA").

The present invention features methods to further enhance pantothenate
20 production by modulating a biosynthetic pathway that supplies a substrate for the pantothenate biosynthetic pathway, namely the methylenetetrahydrofolate ("MTF") biosynthetic pathway. In particular, it has been discovered that increasing levels of MTF by modification of the MTF biosynthetic pathway results in enhanced levels of the key pantothenate biosynthetic pathway intermediate, ketopantoate. Enhanced ketopantoate
25 levels, in turn, result in significantly enhanced pantothenate production levels in appropriately engineered strains. In essence, the present inventors have identified a limiting step in the production of panto-compounds (*e.g.*, pantothenate) by strains engineered to overexpress, for example, the *panB*, *panC*, *panD*, *panE1*, *ilvBNC* and *ilvD* genes, and describe herein a means for overcoming this limitation by modification of the
30 MTF biosynthetic pathway.

At least three effective means of modifying the MTF biosynthetic pathway are described herein. In one aspect, it has been demonstrated that increasing serine levels in the culture medium of pantothenate-producing microorganisms results in enhanced panto-compound production. It has also been demonstrated that increasing the
35 synthesis or activity of 3-phosphoglycerate dehydrogenase (the *serA* gene product), or the synthesis or activity of serine hydroxymethyl transferase (the *glyA* gene product), thereby enhancing serine and methylenetetrahydrofolate biosynthesis in appropriately engineered microorganisms, increases panto-compound production. Increased synthesis

of 3-phosphoglycerate dehydrogenase (the *serA* gene product) is achieved, for example, by overexpressing *serA* from an appropriately-engineered expression cassette. Increased synthesis of serine hydroxymethyl transferase (the *glyA* gene product) is achieved, for example, by overexpressing *glyA* from an appropriately-engineered expression cassette.

- 5 Alternatively, levels of serine hydroxymethyl transferase (the *glyA* gene product) are increased by altering the regulation of the *glyA* gene. For example, mutation or deletion of the gene encoding a negative regulator (*i.e.*, repressor) of *glyA* expression, the *purR* gene, effectively increases *glyA* expression. Additional methods suitable for increasing MTF levels in panto-compound producing microorganisms involve deregulating enzymes
10 responsible for converting glycine to MTF (*e.g.*, glycine cleavage enzymes).

- Accordingly, in one aspect the invention features processes for the enhanced production of pantoate and pantothenate that involve culturing microorganisms having modified pantothenate biosynthetic enzyme activities and having modified methylenetetrahydrofolate (MTF) biosynthetic enzyme activities under conditions such
15 that pantothenate production is enhanced. In another aspect the invention features processes for the enhanced production of pantoate and pantothenate that involve culturing microorganisms having modified pantothenate biosynthetic enzyme activities, having modified isoleucine-valine (*ilv*) biosynthetic enzymes, and having modified methylenetetrahydrofolate (MTF) biosynthetic enzyme activities under conditions such
20 that pantothenate production is enhanced. In particular, the invention features methods for enhancing production of desired products (*e.g.*, pantoate and/or pantothenate) by increasing the levels of a key intermediate, ketopantoate, by enzymes that contribute to its synthesis. Preferred methods result in production of pantothenate at levels greater than 50, 60, 70 or more g/L after 36 hours of culturing the microorganisms, or such that
25 at least 60, 70, 80, 90, 100, 110, 120 or more g/L pantothenate is produced after 36 hours of culturing the microorganisms. Recombinant microorganisms and conditions for culturing same are also featured. Also featured are compositions produced by such microorganisms.

- 30 Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

- 35 *Figure 1* is a schematic representation of the pantothenate and isoleucine-valine (*ilv*) biosynthetic pathways. Pantothenate biosynthetic enzymes are depicted in bold and their corresponding genes indicated in italics. Isoleucine-valine (*ilv*) biosynthetic enzymes are depicted in bold italics and their corresponding genes indicated in italics.

Figure 2 is a schematic representation of the methylenetetrahydrofolate ("MTF") biosynthetic pathway in *E. coli* (and presumably in *B. subtilis*).

Figure 3 is a schematic representation of the construction of the plasmid pAN665.

5 Figure 4 is a schematic representation of the construction of the plasmid pAN670.

Figure 5 is a schematic representation of the plasmid pAN004.

Figure 6 is a schematic representation of the plasmid pAN396.

Figure 7 is a schematic representation of the plasmid pAN393.

10 Figure 8 is a schematic representation of the structure of pAN835F, a clone of the *B. subtilis purR* gene.

Figure 9 is a schematic representation of the structure of pAN838F, a plasmid designed to install a disruption of the *B. subtilis purR* gene.

15 Figure 10 is a schematic representation of the structure of pAN821, a plasmid designed to delete a portion of the *serA* gene, selecting for kanamycin resistance.

Figure 11 is a schematic representation of the structure of pAN824, a plasmid designed to integrate a non-amplifiable *P26 serA* cassette at the *serA* locus, selecting for *Ser*⁺.

20 Figure 12 is a schematic representation of the structure of pAN395, a medium copy plasmid designed to integrate and amplify a *P26 serA* expression cassette at the *serA* locus.

Detailed Description of the Invention

25 The present invention is directed to improved methods for producing panto-compounds (e.g., ketopantoate, pantoate and/or pantothenate) and strains engineered for use in said improved methods. Strains capable of producing > 50 g/l of pantothenate can be constructed as taught in International Patent Application Serial No. WO 01/21772 and in U.S. Patent Application Serial No. 60/262,995. By increasing the
30 expression of the *panB*, *panC*, *panD* and *panE1* genes and by increasing the expression of the *ilvBNC* and *ilvD* genes, one can design strains (e.g., *Bacillus* strains) that convert glucose (pyruvate) to commercially attractive quantities of pantothenate.

However, it has now been discovered that in strains engineered to express high levels of the *panB* gene product, ketopantoate hydroxymethyltransferase (e.g.,
35 PA824, described in U.S. Patent Application Serial No. 09/667,569 and PA668-24, described in U.S. Patent Application Serial No. 60/262,995), a limiting step for further increases in the production of pantothenate is still the conversion of α -ketoisovalerate (α -KIV) to ketopantoate. Methods to increase the synthesis of α -KIV were described

previously in International Patent Application Serial No. WO 01/21772 and U.S. Patent Application Serial No. 60/262,995. Here we disclose that even further increases in pantothenate production can be achieved by engineering panto-compound producing microorganisms such that the level of MTF, or the rate of MTF synthesis is enhanced or
5 increased.

Accordingly, the present invention features methods for improving panto-compound production that involve modulating the methylenetetrahydrofolate ("MTF") biosynthetic pathway. In particular, increasing MTF levels in panto-compound producing microbes is an effective means of enhancing ketopantoate production, and in
10 turn results in enhanced pantoate and/or pantothenate production in appropriately-engineered recombinant microorganisms.

Ketopantoate hydroxymethylenetransferase catalyzes the production of ketopantoate from α -ketoisovalerate (" α -KIV") and MTF (see *e.g.*, Figure 1). In particular, the enzyme catalyzes the transfer of a hydroxymethyl group from MTF to α -
15 KIV to yield ketopantoate. Both α -KIV and MTF are substrates for this reaction, and their syntheses can be increased in order to improve production of ketopantoate. The pathway for MTF biosynthesis in *E. coli* (and also in *Bacillus subtilis*) is outlined in Figure 2. MTF is synthesized from tetrahydrofolate and serine in a reaction catalyzed by the *glyA* gene that encodes serine hydroxymethyl transferase. For improved MTF
20 synthesis the cells need increased quantities of both substrates and the product of the *glyA* gene.

In one embodiment, the invention features processes for the enhanced production of pantothenate that involve culturing a microorganism having (i) a deregulated pantothenate biosynthetic pathway (*e.g.*, having one, two, three or four
25 pantothenate biosynthetic enzymes deregulated) and (ii) a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway (*e.g.*, having at least one or two MTF biosynthetic enzymes deregulated), under conditions such that pantothenate production is enhanced. Exemplary pantothenate biosynthetic enzymes include ketopantoate hydroxymethyltransferase, ketopantoate reductase, pantothenate synthetase and aspartate- α -decarboxylase. Exemplary MTF biosynthetic enzymes include the *serA*
30 gene product and the *glyA* gene product.

In another embodiment, the invention features processes for the enhanced production of pantothenate that involve culturing a microorganism having (i) a deregulated pantothenate biosynthetic pathway (*e.g.*, having one, two, three or four
35 pantothenate biosynthetic enzymes deregulated), (ii) a deregulated isoleucine-valine (*ilv*) biosynthetic pathway (*e.g.*, having one, two or three *ilv* biosynthetic enzymes deregulated), and (iii) a deregulated MTF biosynthetic pathway (*e.g.*, having at least one or two MTF biosynthetic enzymes deregulated), under conditions such that pantothenate

production is enhanced. Exemplary *ilv* biosynthetic enzymes include acetohydroxyacid acid synthetase, acetohydroxyacid isomeroreductase, and dihydroxyacid dehydratase.

In another embodiment, the invention features processes for the production of pantothenate that involve culturing a microorganism having a deregulated
5 pantothenate biosynthetic pathway, a deregulated *ilv* biosynthetic pathway, and a deregulated MTF biosynthetic pathway, such that at least 50 g/L pantothenate is produced after 36 hours of culturing the microorganism, preferably such that at least 60 g/L pantothenate is produced after 36 hours of culturing the microorganism, more preferably such that at least 70 g/L pantothenate is produced after 36 hours of culturing
10 the microorganism, and most preferably such that at least 80 g/L pantothenate, at least 90 g/L pantothenate, at least 100 g/L pantothenate, at least 110 g/L pantothenate, or at least 120 g/L pantothenate (or more) is produced after 36 hours of culturing the microorganism.

In another embodiment, the invention features processes for the
15 production of pantothenate that involve culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated *ilv* biosynthetic pathway, and a deregulated MTF biosynthetic pathway, deregulated such that at least 70 g/L pantothenate is produced after 48 hours of culturing the microorganism, preferably such that at least 80 g/L pantothenate is produced after 48 hours of culturing the
20 microorganism, and more preferably such that at least 90 g/L pantothenate is produced after 48 hours of culturing the microorganism.

In one exemplary embodiment, deregulation of the MTF biosynthetic pathway is achieved by deregulating the *serA* gene product in a panto-compound producing strain, for example, by expressing the *serA* gene constitutively or by
25 introducing a feedback resistant allele of *serA*. In another exemplary embodiment, deregulation of the MTF biosynthetic pathway is achieved by deregulating the *glyA* gene product in a panto-compound producing strain, for example, by overexpressing the *glyA* gene or modulating repression of the *glyA* gene by mutating or disrupting the *purR* gene product. In other exemplary embodiments, MTF biosynthesis is modulated by
30 increasing serine in the culture medium or deregulating glycine cleavage enzymes.

The invention further features methods as described above, wherein pantothenate production is further enhanced by regulating pantothenate kinase activity (e.g., wherein pantothenate kinase activity is decreased). In one embodiment, CoaA is deleted and CoaX is downregulated. In another embodiment, CoaX is deleted and CoaA
35 is downregulated. In yet another embodiment, CoaX and CoaA are downregulated. The invention further features methods as described above, wherein the microorganisms are cultured under conditions of excess serine. The invention further features methods as

described above, wherein the microorganisms have the pantothenate biosynthetic pathway deregulated such that pantothenate production is independent of β -alanine feed.

Products synthesized according to the processes of the invention are also featured, as are compositions that include pantothenate produced according to said
5 processes. Recombinant microorganisms for use in the processes of the invention are also featured. In one embodiment, the invention features a recombinant microorganism for the enhanced production of pantothenate having a deregulated pantothenate biosynthetic pathway and a deregulated MTF biosynthetic pathway. In another
10 embodiment, the invention features a recombinant microorganism for the enhanced production of pantothenate having a deregulated pantothenate biosynthetic pathway, a deregulated MTF biosynthetic pathway and a deregulated *ilv* pathway. Microorganisms can further have reduced pantothenate kinase activity. Preferred microorganisms belong to the genus *Bacillus*, for example *Bacillus subtilis*.

As described above, certain aspects of the invention feature processes for
15 the enhanced production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that involve culturing microorganisms having at least a deregulated pantothenate biosynthetic pathway. The term "pantothenate biosynthetic pathway" includes the biosynthetic pathway involving pantothenate biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, substrates,
20 intermediates or products), cofactors and the like utilized in the formation or synthesis of pantothenate. The term "pantothenate biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of pantothenate in microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of pantothenate *in vitro*.

As used herein, a microorganism "having a deregulated pantothenate
25 biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) (both terms as defined herein) such that pantothenate production is enhanced (*e.g.*, as compared to pantothenate production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism). The term "pantothenate" includes the free
30 acid form of pantothenate, also referred to as "pantothenic acid" as well as any salt thereof (*e.g.*, derived by replacing the acidic hydrogen of pantothenate or pantothenic acid with a cation, for example, calcium, sodium, potassium, ammonium, magnesium), also referred to as a "pantothenate salt". The term "pantothenate" also includes alcohol derivatives of pantothenate. Preferred pantothenate salts are calcium pantothenate or
35 sodium pantothenate. A preferred alcohol derivative is pantothenol. Pantothenate salts and/or alcohols of the present invention include salts and/or alcohols prepared *via* conventional methods from the free acids described herein. In another embodiment, a pantothenate salt is synthesized directly by a microorganism of the present invention. A

pantothenate salt of the present invention can likewise be converted to a free acid form of pantothenate or pantothenic acid by conventional methodology. The term "pantothenate" is also abbreviated as "pan" herein.

Preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) such that pantothenate production is 1 g/L or greater. More preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) such that pantothenate production is 2 g/L or greater. Even more preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) such that pantothenate production is 10 g/L, 20 g/L, 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, or greater.

The term "pantothenate biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the pantothenate biosynthetic pathway. For example, synthesis of pantoate from α -ketoisovalerate (α -KIV) proceeds *via* the intermediate, ketopantoate. Formation of ketopantoate is catalyzed by the pantothenate biosynthetic enzyme PanB or ketopantoate hydroxymethyltransferase (the *panB* gene product). Formation of pantoate is catalyzed by the pantothenate biosynthetic enzyme PanE1 or ketopantoate reductase (the *panE1* gene product). Synthesis of β -alanine from aspartate is catalyzed by the pantothenate biosynthetic enzyme PanD or aspartate- α -decarboxylase (the *panD* gene product). Formation of pantothenate from pantoate and β -alanine (*e.g.*, condensation) is catalyzed by the pantothenate biosynthetic enzyme PanC or pantothenate synthetase (the *panC* gene product). Pantothenate biosynthetic enzymes may also perform an alternative function as enzymes in the HMBPA biosynthetic pathway described herein.

Accordingly, in one embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, deregulated such that pantothenate production is enhanced), said enzyme being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -decarboxylase), PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least two pantothenate biosynthetic enzymes deregulated, said enzymes being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -

decarboxylase), and PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least three pantothenate biosynthetic enzymes deregulated, said enzymes being selected, for example, from the group consisting of

5 PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -decarboxylase), and PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least four pantothenate biosynthetic enzymes deregulated, for example, a microorganism having PanB (or

10 ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -decarboxylase), and PanE1 (or ketopantoate reductase) deregulated.

In another aspect, the invention features processes for the enhanced production of pantothenate that involve culturing microorganisms having a deregulated isoleucine-valine biosynthetic pathway. The term "isoleucine-valine biosynthetic

15 pathway" includes the biosynthetic pathway involving isoleucine-valine biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of conversion of pyruvate to valine or isoleucine. The term "isoleucine-valine biosynthetic pathway" includes the biosynthetic pathway leading to

20 the synthesis of valine or isoleucine in microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of valine or isoleucine *in vitro*.

As used herein, a microorganism "having a deregulated isoleucine-valine (*ilv*) pathway" includes a microorganism having at least one isoleucine-valine (*ilv*) biosynthetic enzyme deregulated (*e.g.*, overexpressed) (both terms as defined herein)

25 such that isoleucine and/or valine and/or the valine precursor, α -ketoisovalerate (α -KIV) production is enhanced (*e.g.*, as compared to isoleucine and/or valine and/or α -KIV production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism). Figure 1 includes a schematic representation of the isoleucine-valine biosynthetic pathway. Isoleucine-valine biosynthetic enzymes

30 are depicted in bold italics and their corresponding genes indicated in italics. The term "isoleucine-valine biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the isoleucine-valine biosynthetic pathway. According to Figure 1, synthesis of valine from pyruvate proceeds *via* the intermediates, acetolactate, α,β -dihydroxyisovalerate (α,β -DHIV) and α -ketoisovalerate

35 (α -KIV). Formation of acetolactate from pyruvate is catalyzed by the isoleucine-valine biosynthetic enzyme acetohydroxyacid synthetase (the *ilvBN* gene products, or alternatively, the *alsS* gene product). Formation of α,β -DHIV from acetolactate is catalyzed by the isoleucine-valine biosynthetic enzyme acetohydroxyacid

isomeroreductase (the *ilvC* gene product). Synthesis of α -KIV from α,β -DHIV is catalyzed by the isoleucine-valine biosynthetic enzyme dihydroxyacid dehydratase (the *ilvD* gene product). Moreover, valine and isoleucine can be interconverted with their respective α -keto compounds by branched chain amino acid transaminases. Isoleucine-valine biosynthetic enzymes may also perform an alternative function as enzymes in the HMBPA biosynthetic pathway described herein.

Accordingly, in one embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least one isoleucine-valine (*ilv*) biosynthetic enzyme deregulated (*e.g.*, deregulated such that valine and/or isoleucine and/or α -KIV production is enhanced), said enzyme being selected, for example, from the group consisting of IlvBN, AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least two isoleucine-valine (*ilv*) biosynthetic enzymes deregulated, said enzyme being selected, for example, from the group consisting of IlvBN, AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least three isoleucine-valine (*ilv*) biosynthetic enzymes deregulated, for example, said microorganism having IlvBN or AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase) deregulated.

As mentioned herein, enzymes of the pantothenate biosynthetic pathway and/or the isoleucine-valine (*ilv*) pathway have been discovered to have an alternative activity in the synthesis of [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") or the [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") biosynthetic pathway. The term "[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") biosynthetic pathway" includes the alternative biosynthetic pathway involving biosynthetic enzymes and compounds (*e.g.*, substrates and the like) traditionally associated with the pantothenate biosynthetic pathway and/or isoleucine-valine (*ilv*) biosynthetic pathway utilized in the formation or synthesis of HMBPA. The term "HMBPA biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of HMBPA in microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of HMBPA *in vitro*.

The term "HMBPA biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the HMBPA biosynthetic pathway. For example, synthesis of 2-hydroxyisovaleric acid (α -HIV) from α -ketoisovalerate (α -KIV) is catalyzed by the *panE1* or *panE2* gene product (PanE1 is

alternatively referred to herein as ketopantoate reductase) and/or is catalyzed by the *ilvC* gene product (alternatively referred to herein as acetohydroxyacid isomeroreductase). Formation of HMBPA from β -alanine and α -HIV is catalyzed by the *panC* gene product (alternatively referred to herein as pantothenate synthetase).

5 The term “[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (“HMBPA”)” includes the free acid form of HMBPA, also referred to as “[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionate” as well as any salt thereof (*e.g.*, derived by replacing the acidic hydrogen of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionate with a cation, for example,
10 calcium, sodium, potassium, ammonium, magnesium), also referred to as a “3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid salt” or “HMBPA salt”. Preferred HMBPA salts are calcium HMBPA or sodium HMBPA. HMBPA salts of the present invention include salts prepared *via* conventional methods from the free acids described herein. An HMBPA salt of the present invention can likewise be converted to a free acid
15 form of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionate by conventional methodology.

 In preferred embodiments, the invention features processes for the enhanced production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that involve culturing a microorganism having a deregulated methylenetetrahydrofolate
20 (MTF) biosynthetic pathway. The term “methylenetetrahydrofolate (MTF) biosynthetic pathway” refers to the biosynthetic pathway involving MTF biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of the PanB substrate, MTF. The term “methylenetetrahydrofolate (MTF)
25 biosynthetic pathway” refers to the biosynthetic pathway leading to the synthesis of MTF *in vivo* (*e.g.*, the pathway in *E. coli*, as depicted in Figure 2) as well as the biosynthetic pathway leading to the synthesis of MTF *in vitro*. The term “methylenetetrahydrofolate (MTF) biosynthetic enzyme” includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the
30 methylenetetrahydrofolate (MTF) biosynthetic pathway.

 The present invention is based, at least in part, on the discovery that deregulation of certain MTF biosynthetic enzymes results in enhanced production of MTF. A MTF biosynthetic enzyme, the deregulation of which results in enhanced MTF production, is termed a “MTF biosynthesis-enhancing enzyme”. Exemplary “MTF
35 biosynthesis-enhancing enzymes” are the *serA* gene product (3-phosphoglycerate dehydrogenase) and the *glyA* gene product (serine hydroxymethyl transferase). A microorganism “having a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway”, is a microorganism having at least one MTF biosynthesis-enhancing enzyme

deregulated (*e.g.*, overexpressed) such that MTF production or biosynthesis is enhanced (*e.g.*, as compared to MTF production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism).

In one embodiment, the invention features a process for the enhanced
5 production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that includes culturing a microorganism having a deregulated “methylenetetrahydrofolate (MTF) biosynthetic pathway”, as defined herein. In another embodiment, the invention features a process for the enhanced production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that includes culturing a microorganism having a deregulated MTF
10 biosynthesis-enhancing enzyme. In preferred embodiments, the invention features processes for the enhanced production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that includes culturing a microorganism having a deregulated *glyA* gene product (serine hydroxymethyl transferase) and/or a deregulated *serA* gene product (3-phosphoglycerate dehydrogenase).

15 Yet another aspect of the present invention features processes for the enhanced production of pantothenate that include culturing microorganisms under culture conditions selected to favor pantothenate production, for example, by culturing microorganisms with excess serine (a *glyA* substrate) in the medium. The term “excess serine” includes serine levels increased or higher than those routinely utilized for
20 culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-2.5 g/L serine. Accordingly, excess serine levels can include levels of greater than 2.5 g/L serine, for example, between about 2.5 and 10 g/L serine. Excess serine levels can include levels of greater than 5 g/L serine, for example, between about 5 and
25 10 g/L serine.

Yet another aspect of the present invention features culturing the microorganisms described herein under conditions such that pantothenate production is further increased, for example, by increasing pantothenate and/or isoleucine-valine (*ilv*) biosynthetic pathway precursors and/or intermediates as defined herein (*e.g.*, culturing
30 microorganisms in the presence of excess β -alanine, valine and/or α -KIV) or, alternatively, further modifying said microorganisms such that they are capable of producing significant levels of β -alanine in the absence of a β -alanine feed (*i.e.*, β -alanine independent microorganisms, as described in U.S. Patent Application Serial No. 09/09/667,569).

35 Yet another aspect of the invention features further regulating pantothenate kinase activity in pantothenate-producing strains such that pantothenate production is enhanced. Pantothenate kinase is a key enzyme catalyzing the formation of Coenzyme A (CoA) from pantothenate (see *e.g.*, U.S. Patent Application Serial No.

09/09/667,569). Regulation of pantothenate kinase (*e.g.*, decreasing the activity or level of pantothenate kinase) reduces the production of CoA, favoring pantothenate accumulation. In one embodiment, pantotheante kinase activity is decreased by deleting CoaA and downregulating CoaX activity (CoaA and CoaX are both capable of catalyzing the first step in CoA biosynthesis in certain microorganisms). In another embodiment, pantothenate kinase activity is decreased by deleting CoaX and downregulating CoaA. In yet another embodiment, pantotheante kinase activity is decreased by downregulating CoaA and CoaX activities.

Various aspects of the invention are described in further detail in the following subsections.

I. Targeting Genes Encoding Various Pantothenate and/or Isoleucine-Valine(*ilv*) and/or Methylenetetrahydrofolate (MTF) Biosynthetic Enzymes

In one embodiment, the present invention features modifying or increasing the level of various biosynthetic enzymes of the pantothenate and/or isoleucine-valine(*ilv*) and/or methylenetetrahydrofolate (MTF) biosynthetic pathways. In particular, the invention features modifying various enzymatic activities associated with said pathways by modifying or altering the genes encoding said biosynthetic enzymes.

The term “gene”, as used herein, includes a nucleic acid molecule (*e.g.*, a DNA molecule or segment thereof) that, in an organism, can be separated from another gene or other genes, by intergenic DNA (*i.e.*, intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). Alternatively, a gene may slightly overlap another gene (*e.g.*, the 3' end of a first gene overlapping the 5' end of a second gene), the overlapping genes separated from other genes by intergenic DNA. A gene may direct synthesis of an enzyme or other protein molecule (*e.g.*, may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. An “isolated gene”, as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences that encode a second or distinct protein, adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Bacillus* proteins). In another embodiment, an isolated

gene includes coding sequences for a protein (*e.g.*, for a *Bacillus* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (*e.g.*, adjacent 5' and/or 3' *Bacillus* regulatory sequences).

Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

The term "operon" includes at least two adjacent genes or ORFs, optionally overlapping in sequence at either the 5' or 3' end of at least one gene or ORF. The term "operon" includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more adjacent genes or ORFs (*e.g.*, structural genes encoding enzymes, for example, biosynthetic enzymes). Expression of the genes (*e.g.*, structural genes) can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The genes of an operon (*e.g.*, structural genes) can be transcribed to give a single mRNA that encodes all of the proteins.

A "gene having a mutation" or "mutant gene" as used herein, includes a gene having a nucleotide sequence which includes at least one alteration (*e.g.*, substitution, insertion, deletion) such that the polypeptide or protein encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. In one embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having an increased activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). As used herein, an "increased activity" or "increased enzymatic activity" is one that is at least 5% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% greater, more preferably at least 10-25% greater and even more preferably at least 25-50%, 50-75% or 75-100% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, an "increased activity" or "increased enzymatic activity" can also include an activity that is at least 1.25-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene, preferably at least 1.5-fold greater, more preferably at least 2-fold greater and even more preferably at least 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene.

In another embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having a reduced activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can encode no polypeptide or have a reduced level of production of the wild-type polypeptide. As used herein, a “reduced activity” or “reduced enzymatic activity” is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a “reduced activity” or “reduced enzymatic activity” can also include an activity that has been deleted or “knocked out” (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene).

Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an activity of a protein in a crude cell extract or isolated or purified from a cell or microorganism. Alternatively, an activity can be measured or assayed within a cell or microorganism or in an extracellular medium. For example, assaying for a mutant gene (*i.e.*, said mutant encoding a reduced enzymatic activity) can be accomplished by expressing the mutated gene in a microorganism, for example, a mutant microorganism in which the enzyme is a temperature-sensitive, and assaying the mutant gene for the ability to complement a temperature sensitive (Ts) mutant for enzymatic activity. A mutant gene that encodes an “increased enzymatic activity” can be one that complements the Ts mutant more effectively than, for example, a corresponding wild-type gene. A mutant gene that encodes a “reduced enzymatic activity” is one that complements the Ts mutant less effectively than, for example, a corresponding wild-type gene.

It will be appreciated by the skilled artisan that even a single substitution in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type polypeptide or protein. A mutant gene (*e.g.*, encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue in that a mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in a microorganism expressing said mutant gene or producing said mutant protein or

polypeptide (*i.e.*, a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene. By contrast, a protein homologue can have an identical or substantially similar activity, optionally phenotypically indiscernable when produced in a microorganism, as compared to a corresponding
5 microorganism expressing the wild-type gene. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (*e.g.*, 30-50% sequence identity)
10 sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

It will also be appreciated by the skilled artisan that nucleic acid molecules, genes, protein or polypeptides for use in the instant invention can be derived
15 from any microorganisms having a MTF biosynthetic pathway, an *ilv* biosynthetic pathway or a pantothenate biosynthetic pathway. Such nucleic acid molecules, genes, protein or polypeptides can be identified by the skilled artisan using known techniques such as homology screening, sequence comparison and the like, and can be modified by the skilled artisan in such a way that expression or production of these nucleic acid
20 molecules, genes, protein or polypeptides occurs in a recombinant microorganism (*e.g.*, by using appropriate promoters, ribosomal binding sites, expression or integration vectors, modifying the sequence of the genes such that the transcription is increased (taking into account the preferable codon usage), etc., according to techniques described herein and those known in the art).

25 In one embodiment, the genes of the present invention are derived from a Gram positive microorganism organism (*e.g.*, a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). The term "derived from" (*e.g.*, "derived from" a Gram positive microorganism) refers to a gene which is naturally found in the microorganism (*e.g.*, is
30 naturally found in a Gram positive microorganism). In a preferred embodiment, the genes of the present invention are derived from a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium* (*e.g.*, *Corynebacterium glutamicum*), *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the genes of the present invention are derived from a microorganism is of
35 the genus *Bacillus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*,

Bacillus licheniformis, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the gene is derived from *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*. In a particularly preferred embodiment, the gene is derived from *Bacillus subtilis* (e.g., is *Bacillus subtilis*-derived). The term “derived from *Bacillus subtilis*” or “*Bacillus subtilis*-derived” includes a gene which is naturally found in the microorganism *Bacillus subtilis*. Included within the scope of the present invention are *Bacillus*-derived genes (e.g., *B. subtilis*-derived genes), for example, *Bacillus* or *B. subtilis purR* genes, *serA* genes, *glyA* genes, *coaX* genes, *coaA* genes, *pan* genes and/or *ilv* genes.

In another embodiment, the genes of the present invention are derived from a Gram negative (excludes basic dye) microorganism. In a preferred embodiment, the genes of the present invention are derived from a microorganism belonging to a genus selected from the group consisting of *Salmonella* (e.g., *Salmonella typhimurium*), *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the genes of the present invention are derived from a microorganism of the genus *Escherichia*. In an even more preferred embodiment, the genes of the present invention are derived from *Escherichia coli*. In another embodiment, the genes of the present invention are derived from *Saccharomyces* (e.g., *Saccharomyces cerevisiae*).

II. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include genes described herein (e.g., isolated genes), preferably *Bacillus* genes, more preferably *Bacillus subtilis* genes, even more preferably *Bacillus subtilis* pantothenate biosynthetic genes and/or isoleucine-valine (*ilv*) biosynthetic genes and/or methylenetetrahydrofolate (MTF) biosynthetic genes. The term “recombinant nucleic acid molecule” includes a nucleic acid molecule (e.g., a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (e.g., a recombinant DNA molecule) includes an isolated gene of the present invention operably linked to regulatory sequences. The phrase “operably linked to regulatory sequence(s)” means that the nucleotide sequence of the gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (e.g.,

enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the gene, preferably expression of a gene product encoded by the gene (*e.g.*, when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism).

5 The term “regulatory sequence” includes nucleic acid sequences which affect (*e.g.*, modulate or regulate) expression of other nucleic acid sequences (*i.e.*, genes). In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it
10 appears in nature, *e.g.*, in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (*e.g.*, operably linked to “native” regulatory sequences (*e.g.*, to the “native” promoter). Alternatively, a gene of interest can be included in a recombinant
15 nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to another (*e.g.*, a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (*e.g.*, other bacterial regulatory sequences, bacteriophage regulatory
20 sequences and the like) can be operably linked to a particular gene of interest.

 In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (*e.g.*, a sequence which has been modified, mutated, substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-
25 termination signals and other expression control elements (*e.g.*, sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring
30 Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (*e.g.*, constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (*e.g.*, inducible promoters, for example, xylose inducible promoters) and those which attenuate or
35 repress expression of a nucleotide sequence in a microorganism (*e.g.*, attenuation signals or repressor binding sequences, for example, a PurR binding site). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative

regulation of transcription can be removed such that expression of a gene of interest is enhanced.

In one embodiment, a recombinant nucleic acid molecule of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (e.g., a pantothenate biosynthetic enzyme, an isoleucine-valine biosynthetic enzyme and/or a methylenetetrahydrofolate (MTF) biosynthetic enzyme) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Bacillus* promoters and/or bacteriophage promoters (e.g., bacteriophage which infect *Bacillus*). In one embodiment, a promoter is a *Bacillus* promoter, preferably a strong *Bacillus* promoter (e.g., a promoter associated with a biochemical housekeeping gene in *Bacillus* or a promoter associated with a glycolytic pathway gene in *Bacillus*). In another embodiment, a promoter is a bacteriophage promoter. In a preferred embodiment, the promoter is from the bacteriophage SP01. In a particularly preferred embodiment, a promoter is selected from the group consisting of *P*₁₅, *P*₂₆ or *P*_{veg}, having for example, the following respective sequences:

GCTATTGACGACAGCTATGGTTCCTGAGGGGTACAAAGAGGTGTCCTAGAAGAGAT
 ACCGCCAATATTTCTCCCTTGAGGGGTACAAAGAGGTGTCCTAGAAGAGAT
 CCACGCTGTGTAAAAATTTACAAAAAGGTATTGACTTTCCCTACAGGGTGT
 GTAATAATTTAATTACAGGCGGGGGCAACCCCGCCTGT (SEQ ID NO:1),

GCCTACCTAGCTTCCAAGAAAGATATCCTAACAGCACAAGAGCGGAAAGAT
 GTTTTGTCTACATCCAGAACAACCTCTGCTAAAATTCCTGAAAAATTTTGCA
 AAAAGTTGTTGACTTTATCTACAAGGTGTGGTATAATAATCTTAACAACAGC
 AGGACGC (SEQ ID NO:2), and

GAGGAATCATAGAATTTTGTCAAAATAATTTTATTGACAACGTCTTATTAAC
 GTTGATATAATTTAAATTTTATTTGACAAAAATGGGCTCGTGTGTACAATA
 AATGTAGTGAGGTGGATGCAATG (SEQ ID NO:3). Additional preferred promoters include *tef* (the translational elongation factor (TEF) promoter) and *pyc* (the pyruvate carboxylase (PYC) promoter), which promote high level expression in *Bacillus* (e.g., *Bacillus subtilis*). Additional preferred promoters, for example, for use in Gram positive microorganisms include, but are not limited to, *amy* and SPO2 promoters. Additional preferred promoters, for example, for use in Gram negative microorganisms include, but are not limited to, *cos*, *tac*, *trp*, *tet*, *trp-tet*, *lpp*, *lac*, *lpp-lac*, *lacIQ*, T7, T5, T3, *gal*, *trc*, *ara*, SP6, λ -PR or λ -PL.

In another embodiment, a recombinant nucleic acid molecule of the present invention includes a terminator sequence or terminator sequences (e.g., transcription terminator sequences). The term "terminator sequences" includes regulatory sequences that serve to terminate transcription of mRNA. Terminator

sequences (or tandem transcription terminators) can further serve to stabilize mRNA (*e.g.*, by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes sequences that allow for detection of the vector containing
 5 said sequences (*i.e.*, detectable and/or selectable markers), for example, genes that encode antibiotic resistance sequences or that overcome auxotrophic mutations, for example, *trpC*, drug markers, fluorescent markers, and/or colorimetric markers (*e.g.*, *lacZ*/ β -galactosidase). In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes an artificial ribosome binding site (RBS) or a sequence
 10 that gets transcribed into an artificial RBS. The term "artificial ribosome binding site (RBS)" includes a site within an mRNA molecule (*e.g.*, coded within DNA) to which a ribosome binds (*e.g.*, to initiate translation) which differs from a native RBS (*e.g.*, a RBS found in a naturally-occurring gene) by at least one nucleotide. Preferred artificial RBSs include about 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24, 25-26, 27-
 15 28, 29-30 or more nucleotides of which about 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-15 or more differ from the native RBS (*e.g.*, the native RBS of a gene of interest, for example, the native *panB* RBS TAAACATGAGGAGGAGAAAACATG (SEQ ID NO:4) or the native *panD* RBS ATTCGAGAAATGGAGAGAATATAATATG (SEQ ID NO:5)). Preferably, nucleotides that differ are substituted such that they are identical to one or
 20 more nucleotides of an ideal RBS when optimally aligned for comparisons. Ideal RBSs include, but are not limited to, AGAAAGGAGGTGA (SEQ ID NO:6), TTAAGAAAGGAGGTGANNNNATG (SEQ ID NO:7), TTAGAAAGGAGGTGANNNNNATG (SEQ ID NO:8), AGAAAGGAGGTGANNNNNNNATG (SEQ ID NO:9), and
 25 AGAAAGGAGGTGANNNNNNNATG (SEQ ID NO:10). Artificial RBSs can be used to replace the naturally-occurring or native RBSs associated with a particular gene. Artificial RBSs preferably increase translation of a particular gene. Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *panB*, for example, of *B. subtilis panB*) include CCCTCTAGAAGGAGGAGAAAACATG (SEQ ID NO:11) and
 30 CCCTCTAGAGGAGGAGAAAACATG (SEQ ID NO:12). Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *panD*, for example, of *B. subtilis panD*) include TTAGAAAGGAGGATTAAATATG (SEQ ID NO:13), TTAGAAAGGAGGTTTAATTAATG (SEQ ID NO:14), TTAGAAAGGAGGTGATTAAATG (SEQ ID NO:15),
 35 TTAGAAAGGAGGTGTTTAAAATG (SEQ ID NO:16), ATTCGAGAAAGGAGG TGAATATAATATG (SEQ ID NO:17), ATTCGAGAAAGGAGGTGAATAATAATG (SEQ ID NO:18), and ATTCGTAGAAAGGAGGTGAATTAATATG (SEQ ID NO:19).

The present invention further features vectors (*e.g.*, recombinant vectors) that include nucleic acid molecules (*e.g.*, genes or recombinant nucleic acid molecules comprising said genes) as described herein. The term "recombinant vector" includes a vector (*e.g.*, plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid
5 vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a biosynthetic enzyme-encoding gene or recombinant nucleic acid molecule including said gene, operably linked to regulatory sequences, for
10 example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSs), as defined herein. In another embodiment, a recombinant vector of the present invention includes sequences that enhance replication in bacteria (*e.g.*, replication-enhancing sequences). In one embodiment, replication-enhancing sequences function in *E. coli*. In another embodiment, replication-enhancing sequences are derived
15 from pBR322.

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance sequences. The term "antibiotic resistance sequences" includes sequences which promote or confer resistance to antibiotics on the host organism (*e.g.*, *Bacillus*). In one embodiment, the antibiotic resistance sequences are
20 selected from the group consisting of *cat* (chloramphenicol resistance) sequences, *tet* (tetracycline resistance) sequences, *erm* (erythromycin resistance) sequences, *neo* (neomycin resistance) sequences, *kan* (kanamycin resistance) sequences and *spec* (spectinomycin resistance) sequences. Recombinant vectors of the present invention can further include homologous recombination sequences (*e.g.*, sequences designed to allow
25 recombination of the gene of interest into the chromosome of the host organism). For example, *bpr*, *vpr*, or *amyE* sequences can be used as homology targets for recombination into the host chromosome. It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice of microorganism to be genetically engineered, the level of expression of gene product
30 desired and the like.

III. Recombinant Microorganisms

The present invention further features microorganisms, *i.e.*, recombinant microorganisms, that include vectors or genes (*e.g.*, wild-type and/or mutated genes) as
35 described herein. As used herein, the term "recombinant microorganism" includes a microorganism (*e.g.*, bacteria, yeast cell, fungal cell, etc.) that has been genetically altered, modified or engineered (*e.g.*, genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (*e.g.*, when the genetic

modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived.

In one embodiment, a recombinant microorganism of the present invention is a Gram positive organism (e.g., a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Cornyebacterium* (e.g., *Cornyebacterium glutamicum*), *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Bacillus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the recombinant microorganism is *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*.

In another embodiment, the recombinant microorganism is a Gram negative (excludes basic dye) organism. In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Salmonella* (e.g., *Salmonella typhimurium*), *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the recombinant microorganism is of the genus *Escherichia*. In an even more preferred embodiment, the recombinant microorganism is *Escherichia coli*. In another embodiment, the recombinant microorganism is *Saccharomyces* (e.g., *Saccharomyces cerevisiae*).

A preferred "recombinant" microorganism of the present invention is a microorganism having a deregulated pantothenate biosynthesis pathway or enzyme, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway or enzyme and/or a modified or deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway or enzyme. The term "deregulated" or "deregulation" includes the alteration or modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased. The phrase "deregulated pathway" includes a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that

the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to “deregulate” a pathway (*e.g.*, to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism in some cases arises from the particular phenomenon of microorganisms in which more than one enzyme (*e.g.*, two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an “operon” (defined herein). Due to the coordinated regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of the expression of each gene product encoded by the operon. Alteration or modification of a regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of a gene or operon, altering nucleic acid sequences adjacent to a gene or operon (or within an operon) such as a ribosome binding site, increasing the copy number of a gene or operon, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a gene or operon and/or translation of a gene product or gene products of a gene or operon, respectively, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Deregulation can also involve altering the coding region of one or more genes to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

In another preferred embodiment, a recombinant microorganism is designed or engineered such that at least one pantothenate biosynthetic enzyme, at least one isoleucine-valine biosynthetic enzyme, and/or at least one MTF biosynthetic enzyme is overexpressed. The term “overexpressed” or “overexpression” includes expression of a gene product (*e.g.*, a biosynthetic enzyme) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically designed or engineered to overexpress a level of gene product greater than that expressed in a comparable microorganism which has not been engineered.

Genetic engineering can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the copy number of a

particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Genetic engineering can also include deletion of a gene, for example, to block a pathway or to remove a repressor.

In another embodiment, the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased. Alternatively, a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.

IV. Culturing and Fermenting Recombinant Microorganisms

The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (*e.g.*, maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a microorganism of the invention is cultured in media (*e.g.*, a sterile, liquid medium) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism (*e.g.*, carbon sources or carbon substrate, for example carbohydrate, hydrocarbons, oils, fats, fatty acids, organic acids, and alcohols; nitrogen sources, for example, peptone, yeast extracts, meat extracts, malt extracts, soy meal, soy flour, soy grits, urea, ammonium sulfate, ammonium chloride, ammonium nitrate and ammonium phosphate; phosphorus sources, for example, phosphoric acid, sodium and potassium salts thereof; trace elements, for example, magnesium, iron, manganese, calcium, copper, zinc, boron, molybdenum, and/or cobalt salts; as well as growth factors such as amino acids, vitamins, growth promoters and the like).

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired product (*e.g.*, pantoate and/or pantothenate). In one embodiment microorganisms are cultured at a pH of about 7. In another embodiment,

microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration
5 (e.g., oxygen) to result in production of the desired product (e.g., pantoate and/or pantothenate). In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or
10 shaking the culture vessel (e.g., tube or flask) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (e.g., through the fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (e.g., *via* addition of antifoaming agents).

Moreover, microorganisms of the present invention can be cultured under
15 controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired product (e.g., pantoate and/or pantothenate). In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between
20 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 50°C.

Microorganisms can be cultured (e.g., maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (e.g., rotary
25 shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (e.g., a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous processes or methods of fermentation.

30 The phrase "batch process" or "batch fermentation" refers to a system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-
35 batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (e.g., added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation

media is added continuously to a fermentor and an equal amount of used or “conditioned” media is simultaneously removed, preferably for recovery of the desired product (*e.g.*, pantoate and/or pantothenate). A variety of such processes have been developed and are well-known in the art.

5 The phrase “culturing under conditions such that a desired compound is produced” includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired compound or to obtain desired yields of the particular compound being produced. For example, culturing is continued for a time sufficient to produce the
10 desired amount of a compound (*e.g.*, pantoate and/or pantothenate). Preferably, culturing is continued for a time sufficient to substantially reach suitable production of the compound (*e.g.*, a time sufficient to reach a suitable concentration of pantoate and/or pantothenate or suitable ratio of pantoate and/or pantothenate:HMBPA). In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment,
15 culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 5 to 10 g/L of compound are produced in about 36 hours, at least about 10 to 20 g/L
20 compound are produced in about 48 hours, or at least about 20 to 30 g/L compound in about 72 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 5 to 20 g/L of compound are produced in about 36 hours, at least about 20 to 30 g/L compound are produced in about 48 hours, or at least about 30 to 50 or 60 g/L compound in about 72 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 40 to 60 g/L of
25 compound are produced in about 36 hours, or at least about 60 to 90 g/L compound are produced in about 48 hours. It will be appreciated by the skilled artisan that values above the upper limits of the ranges recited may be obtainable by the processes described herein, for example, in a particular fermentation run or with a particular engineered strain.

30

 Preferably, a production method of the present invention results in production of a level of pantothenate that is “enhanced as compared to an appropriate control”. The term “appropriate control”, as defined herein, includes any control recognized by the skilled artisan as being appropriate for determining enhanced,
35 increased, or elevated levels of desired product. For example, where the process features culturing a microorganism having a deregulated pantothenate biosynthetic pathway and said microorganism further has a deregulated MTF biosynthetic pathway (*i.e.*, has been engineered such that at least one MTF biosynthetic enzyme is deregulated, for example,

overexpressed) an appropriate control includes a culture of the microorganism before or absent manipulation of the MTF enzyme or pathway (*i.e.*, having only the pantothenate biosynthetic pathway deregulated). Likewise, where the process features culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a
5 deregulated *ilv* biosynthetic pathway and said microorganism further has a deregulated MTF biosynthetic pathway (*i.e.*, has been engineered such that at least one MTF biosynthetic enzyme is deregulated, for example, overexpressed) an appropriate control includes a culture of the microorganism before or absent manipulation of the MTF
10 enzyme or pathway (*i.e.*, having only the pantothenate biosynthetic pathway and *ilv* biosynthetic pathway deregulated). Comparison need not be performed in each process practiced according to the present invention. For example, a skilled artisan can determine appropriate controls empirically from performing a series of reactions (*e.g.*, test tube cultures, shake flask cultures, fermentations), for example, under the same or similar conditions. Having appreciated a routine production level, for example, by a
15 particular strain, the artisan is able to recognize levels that are enhanced, increased or elevated over such levels. In other words, comparison to an appropriate control includes comparison to a predetermined values (*e.g.*, a predetermined control).

Thus, in an embodiment wherein an appropriately engineered strain produces 40 g/L pantothenate in 36 hours (prior to manipulation such that pantothenate
20 production is enhanced), production of 50, 60, 70 or more g/L pantothenate (after manipulation, for example, manipulation such that at least one MTF biosynthetic enzyme is overexpressed) exemplifies enhanced production. Likewise, in an embodiment wherein an appropriately engineered strain produces 50 g/L pantothenate in 48 hours (prior to manipulation such that pantothenate production is enhanced),
25 production of 60, 70, 80, 90 or more g/L pantothenate (after manipulation, for example, manipulation such that at least one MTF biosynthetic enzyme is overexpressed) exemplifies enhanced production.

The methodology of the present invention can further include a step of recovering a desired compound (*e.g.*, pantoate and/or pantothenate). The term
30 "recovering" a desired compound includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*, anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional
35 adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example, a compound

can be recovered from culture media by first removing the microorganisms from the culture. Media are then passed through or over a cation exchange resin to remove cations and then through or over an anion exchange resin to remove inorganic anions and organic acids having stronger acidities than the compound of interest. The resulting
5 compound can subsequently be converted to a salt (*e.g.*, a calcium salt) as described herein.

Preferably, a desired compound of the present invention is “extracted”, “isolated” or “purified” such that the resulting preparation is substantially free of other media components (*e.g.*, free of media components and/or fermentation byproducts).
10 The language “substantially free of other media components” includes preparations of the desired compound in which the compound is separated from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more
15 preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (*e.g.*, less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (*e.g.*, less than about 1-2% other media components or fermentation
20 byproducts). When the desired compound has been derivatized to a salt, the compound is preferably further free of chemical contaminants associated with the formation of the salt. When the desired compound has been derivatized to an alcohol, the compound is preferably further free of chemical contaminants associated with the formation of the alcohol.

25 In an alternative embodiment, the desired compound is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) is used without modification. In another embodiment, the culture (or
30 culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

In yet another embodiment, the desired compound is partially purified. The term “partially purified” includes media preparations that have had at least some processing, for example, treatment (*e.g.*, batch treatment) with a commercial resin. In
35 preferred embodiments, the “partially purified” preparation has greater than about 30% (by dry weight) of the desired compound, preferably greater than about 40% of the desired compound, more preferably greater than about 50% of the desired compound, still more preferably greater than about 60% of the desired compound, and most

preferably greater than about 70% desired compound. "Partially purified" preparations also preferably have 80% or less (by dry weight) of the desired compound (*i.e.*, are less pure than "extracted", "isolated" or "purified" preparations, as defined herein).

Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one biosynthetic precursor such that the desired compound or compounds are produced. The term "biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase biosynthesis of the desired product. In one embodiment, the biosynthetic precursor or precursor is aspartate. In another embodiment, the biosynthetic precursor or precursor is β -alanine. The amount of aspartate or β -alanine added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity of the microorganism (*e.g.*, a concentration sufficient to enhance production of pantoate and/or pantothenate). Biosynthetic precursors of the present invention can be added in the form of a concentrated solution or suspension (*e.g.*, in a suitable solvent such as water or buffer) or in the form of a solid (*e.g.*, in the form of a powder). Moreover, biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time. The term "excess β -alanine" includes β -alanine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.01 g/L β -alanine. Accordingly, excess β -alanine levels can include levels of about 0.01-1, preferably about 1-20 g/L.

In yet another embodiment, the biosynthetic precursor is valine. In yet another embodiment, the biosynthetic precursor is α -ketoisovalerate. Preferably, valine or α -ketoisovalerate is added in an amount that results in a concentration in the medium sufficient for production of the desired product (*e.g.*, pantoate and/or pantothenate) to occur. The term "excess α -KIV" includes α -KIV levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.01 g/L α -KIV. Accordingly, excess α -KIV levels can include levels of about 0.01-1, preferably about 1-20 g/L α -KIV. The term "excess valine" includes valine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.5 g/L valine. Accordingly, excess valine levels can include levels of about 0.5-5 g/L, preferably about 5-20 g/L valine.

In yet another embodiment, the biosynthetic precursor is serine.

Preferably, serine is added in an amount that results in a concentration in the medium sufficient for production of the desired product (*e.g.*, pantoate and/or pantothenate) to occur. Excess serine (as defined herein) can also be added according to the production processes described herein, for example, for the enhanced production of pantothenate. The skilled artisan will appreciate that extreme excesses of biosynthetic precursors can result in microorganism toxicity. Biosynthetic precursors are also referred to herein as “supplemental biosynthetic substrates”.

Another aspect of the present invention includes biotransformation processes which feature the recombinant microorganisms described herein. The term “biotransformation process”, also referred to herein as “bioconversion processes”, includes biological processes which results in the production (*e.g.*, transformation or conversion) of appropriate substrates and/or intermediate compounds into a desired product.

The microorganism(s) and/or enzymes used in the biotransformation reactions are in a form allowing them to perform their intended function (*e.g.*, producing a desired compound). The microorganisms can be whole cells, or can be only those portions of the cells necessary to obtain the desired end result. The microorganisms can be suspended (*e.g.*, in an appropriate solution such as buffered solutions or media), rinsed (*e.g.*, rinsed free of media from culturing the microorganism), acetone-dried, immobilized (*e.g.*, with polyacrylamide gel or k-carrageenan or on synthetic supports, for example, beads, matrices and the like), fixed, cross-linked or permeablized (*e.g.*, have permeablized membranes and/or walls such that compounds, for example, substrates, intermediates or products can more easily pass through said membrane or wall).

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

EXAMPLES

Example I: Panto-Compound Production Strains

In developing *Bacillus* strains for the production of pantothenate, various genetic manipulations are made to genes and enzymes involved in the pantothenate biosynthetic pathway and the isoleucine-valine (*ilv*) pathway (Figure 1) as described in U.S. Patent Application Serial No. 09/400,494 and U.S. Patent Application Serial No. 09/667,569. For example, strains having a deregulated *panBCD* operon and/or having deregulated *panE1* exhibit enhanced pantothenate production (when cultured in the presence of β -alanine and α -ketoisovalerate (α -KIV)). Strains further deregulated for *ilvBNC* and *ilvD* exhibit enhanced pantothenate production in the presence of only β -alanine. Moreover, it is possible to achieve β -alanine independence by further deregulating *panD*.

An exemplary pantothenate production strain is PA824, a tryptophan prototroph, Spec and Tet resistant, deregulated for *panBCD* at the *panBCD* locus, deregulated for *panE1* at the *panE1* locus (two genes in the *B. subtilis* genome are homologous to *E. coli panE*, *panE1* and *panE2*, the former encoding the major ketopantoate reductase involved in pantothenate production, while *panE2* does not contribute to pantothenate synthesis (U.S. Patent Application Serial No. 09/400,494), deregulated for *ilvD* at the *ilvD* locus, overexpressing an *ilvBNC* cassette at the *amyE* locus, and overexpressing *panD* at the *bpr* locus. PA824 routinely yields approximately 40-50 g/L pantothenate, when cultured for 48 hours in 14 L fermentor vessels according to standard fermentation procedures (see *e.g.*, provisional Patent Application Serial No. 60/263,053 or provisional Patent Application Serial No. 60/262,995, incorporated by reference herein). Briefly, batch media (4.5 L) containing trace elements is inoculated with shake flask cultures of PA824. The fermentations are controlled for temperature (*e.g.*, 43°C), dissolved O₂, and pH, and are run as a glucose limited fed batch process. After the initial batched glucose is consumed, glucose concentrations are maintained between about 0 and 1 g/L by continuous feeding of fresh FEED media. pH is set at 7.2, monitored, and maintained by feeding either a NH₃- or a H₃PO₄-solution. The dissolved oxygen concentration [pO₂] is maintained at about 10-30% by regulation of the agitation and aeration rate. Foaming is controlled by addition of an appropriate antifoam agent. The pantothenate titer in the fermentation broth is determined (by HPLC analysis) after removal of the cells by centrifugation.

A second exemplary strain is PA668. PA668 is a derivative of PA824 that contains extra copies of *P*₂₆ *panB* amplified at the *vpr* and/or *panB* locus. PA668 was constructed using a *panB* expression vector (pAN636) which allows for selection of multiple copies using chloramphenicol. Briefly, a pAN636 *NotI* restriction fragment

(excluding vector sequences) was ligated and then used to transform PA824 with selection on plates containing 5 µg/ml chloramphenicol. Transformants resistant to 30 µg/ml chloramphenicol were isolated and screened for pantothenate production in 48 hour test tube cultures. The isolates produce about 10 percent more pantothenate than PA824. In 10-L fermentations, a first strain, PA668-2A, produces pantothenate in amounts comparable to PA824 cultured under similar conditions (*e.g.*, ~45-50 g/L at 36 hours). After 36 hours, when pantothenate production routinely begins to slow with PA824, PA668-2A continues to produce significant levels of pantothenate (*e.g.*, ~60-65 g/l pantothenate at 48 hours). A second strain, PA668-24, produces pantothenate at an even faster rate, reaching 60-70 g/L after 48 hours.

A third production strain, PA721B-39, was engineered to further include an amplifiable *P₂₆ panBpanD* cassette as follows. First, a single expression cassette was constructed that is capable of integrating both *panB* and *panD* at the *bpr* locus. Combining both genes into one expression cassette simplifies the resulting strain by eliminating an antibiotic resistance marker. The *P₂₆ panBpanD* expression cassette was constructed to include each of two different *panD* ribosome binding sites (the RBSs having previously been synthesized and tested in International Public. No. WO 01/21772 and U.S. Patent Application No. 60/262,995). The cassette further included the synthetic *panB* gene ribosome binding site (RBS1), but the design permits future alteration of the *panB* RBS by simple oligonucleotide cassette substitution. In the first step of construction, the *panB* gene was joined to the two *panD* gene cassettes as illustrated in Figure 3 for the construction of pAN665. Next, the resulting *panBpanD* cassettes were transferred to *B. subtilis* expression vector pOTP61 as illustrated in Figure 4. A summary of the essential features of each plasmid (pAN670 and pAN674) constructed is presented in Table 1.

Table 1. Plasmids containing various *B. subtilis* panBpanD gene expression cassettes.

Plasmid	<i>panD</i> RBS	Vector	Host strain
pAN665	Standard	pASK-1BA3	<i>E. coli</i>
pAN670	“	pOTP61	<i>B. subtilis</i>
pAN669	ND-C2	pASK-1BA3	<i>E. coli</i>
pAN674	“	pOTP61	<i>B. subtilis</i>

These new plasmids combine production of extra PanB and PanD from a single vector and were predicted to produce increased levels of PanB relative to the *panB* expression vector (pAN636) present in PA668. The strategy to install the *P26 panBpanD* vectors in pantothenate production strains took advantage of genetic linkage between *bpr* and *panE1*. A derivative of PA824 was first constructed that is cured of the resident *panD* expression cassette by transforming the strain with chromosomal DNA isolated from PA930 (*panE1::cat*) and selecting for resistance to chloramphenicol. The resulting transformants were screened for sensitivity to tetracycline, and two Tet-sensitive isolates named PA715 were saved. This strain is the host strain for testing the *P26 panBpanD* vectors (see below). In order to restore the *P26 panE1* cassette in PA715, each vector was first transformed into a strain (PA328) that contains *P26 panE1* but does not contain a cassette integrated at the *bpr* locus. PA328 does contain the *P26 panBCD* locus although it is not engineered for overproduction of α -KIV. Transformants of PA328 resistant to tetracycline were obtained using the appropriate *NotI* restriction fragments from the two vectors and the resulting strains were named PA710 and PA714.

The next step was to transfer the cassettes into PA715 so they could be evaluated in the PA824 strain background. This was accomplished by isolating chromosomal DNA from strains PA710 and PA714 and using each of the two DNAs separately to transform PA715, with selection for resistance to tetracycline. Tetracycline-resistant transformants were screened for sensitivity to chloramphenicol; this identifies the desired transformants that have also acquired the *P26 panE1* gene from the donor DNA by linkage with the *P26 panBpanD* cassettes at the *bpr* locus. Chloramphenicol-sensitive isolates derived from transformations in which PA710 or PA714 chromosomal DNA was used as the donor were obtained. The isolates that produced the highest pantothenate titers in test tube culture assays were saved. These strains were named PA717 and PA721, respectively. Duplicate test tube cultures of the new strains, as well as PA824 and PA715, were grown in SVY + 10 g/L aspartate at 43°C for 48 hours and then assayed for pantothenate, HMBPA, and β -alanine. In addition, extracts from each of the strains were run on a SDS-PAGE gel. The results of the test tube culture assays are presented in Table 2.

Table 2. *Production of pantothenate by strains PA717 and PA721 grown in SVY plus 10 g/l aspartate.*

Strain	<i>panBD</i> cassette	[pan] (g/L)	[HMBPA] (g/L)	[β -ala] (g/L)
PA824	-	4.9	0.94	2.5
"		4.6	0.79	2.3
PA715	NONE	1.7	<0.1	0.5
"	"	1.7	<0.1	0.4
PA717-24	pAN670	4.8	0.34	1.3
"	"	4.9	0.40	1.3
PA721-35	pAN674	5.7	0.50	1.4
"	"	5.3	0.40	1.3
PA721-39	pAN674	4.1	0.38	2.0
"	"	4.6	0.40	2.2

5

As expected, each of the new strains produced more pantothenate and β -alanine than PA715. Two of the strains (PA717-24 and PA721-39) produced about as much pantothenate as PA824 while PA721-35 produced more pantothenate than PA824. All three of the new strains produced less HMBPA than PA824. The protein gel
 10 analysis showed that the three new strains produce more PanB than any of the control strains.

Strains PA717-24, PA721-35, and PA721-39 were also evaluated in shake flask cultures in a soy flour based medium. As shown in Table 3, these strains with the amplifiable *P*₂₆ *panBpanD* cassette produced pantothenate and HMBPA at
 15 levels similar to the levels seen with PA668-2 and PA668-24 which both contain separate amplifiable *P*₂₆ *panB* and *P*₂₆ *panD* cassettes.

Table 3. Shake Flask Experiment 48 Hours

Medium	Strain	HMBPA (g/l)	PAN (g/l)
Soy flour + Glucose	PA668-2	1.2	6.8
	PA668-24	1.6	5.2
	PA717-24	2.0	5.9
	PA721-35	2.6	7.0
	PA721-39	2.5	8.6
Soy flour + Maltose	PA668-2	0.0	9.0
	PA668-24	0.4	10.4
	PA717-24	0.7	8.6
	PA721-35	1.0	9.2
	PA721-39	0.4	9.1

Conditions: 40ml medium / 200ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum (1.0 ml).

Soy Medium: 20 g/l Cargill 200/20 soy flour, 8 g/l (NH₄)₂SO₄, 5g/l glutamate, 1x PSTE, 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2. 60 g/l glucose or maltose w/ 10 mM Mg and 1.4 mM Ca.

Average of duplicate flasks.

In addition to producing pantothenate (as well as other panto-compounds depicted in Figure 1 and described herein), it has been demonstrated that certain strains engineered for producing commercial quantities of desired panto-compound also produce a by-product identified as 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (HMBPA) (also referred to herein as “ β -alanine 2-(*R*)-hydroxyisovalerate”, “ β -alanine 2-hydroxyisovalerate”, “ β -alanyl- α -hydroxyisovalerate” and/or “pantothenate”). (The term “pantothenate” is also abbreviated as “fan” herein.)

HMBPA is the condensation product of [*R*]- α -hydroxyisovaleric acid (α -HIV) and β -alanine, catalyzed by the PanC enzyme. α -HIV is generated by reduction of α -KIV, a reaction that is catalyzed by the α -keto reductases PanE (*e.g.*, PanE1 and/or PanE2) and/or IlvC. Thus it has been proposed that there exist at least two pathways in microorganisms that compete for α -KIV, the substrate for the biosynthetic enzyme PanB, namely the pantothenate biosynthetic pathway and the HMBPA biosynthetic

pathway. (A third and fourth pathway competing for α -KIV are those resulting in the production of valine or leucine from α -KIV, see *e.g.*, Figure 1). At least the pantothenate biosynthetic pathway and the HMBPA biosynthetic pathway further produce competitive substrates for the enzyme PanC, namely α -HIV and pantoate.

- 5 Production of HMBPA can have significant effects on pantothenate production. For example, the HMBPA pathway can compete with the pantothenate pathway for precursors (α -KIV and β -alanine) and for some of the enzymes (PanC, PanD, PanE1, and/or IlvC). In addition, because the structure of HMBPA is similar to that of pantothenate, it may have the undesirable property of negatively regulating one or more
- 10 steps in the pantothenate pathway. Based on the identification of HMBPA, U.S. Provisional Patent Application Ser. No. 60/262,995 teaches that production of pantothenate can be improved or optimized by any means which favor use of substrates (α -KIV and β -alanine) and/or enzymes (PanC, PanD, PanE1, and/or IlvC) in pantothenate biosynthetic processes as compared to HMBPA biosynthetic processes.

15

Example II: Increasing Pantothenate Production by Increasing Serine Availability

- At least one method for optimizing pantothenate production involves regulating the availability of serine in the microorganism cultures. In particular, it can
- 20 be demonstrated that increasing the availability of serine leads to increased pantothenate production (*e.g.*, relative to HMBPA production), whereas decreasing the availability of serine leads to decreased pantothenate production relative to HMBPA production. This method is based on the understanding that the compound, methylenetetrahydrofolate (MTF), which is derived from serine, donates a hydroxymethyl group to α -KIV during
- 25 the pantothenate biosynthetic reaction to yield ketopantoate (see *e.g.*, Figures 1 and 2). Thus, regulating serine levels is one means of effectively regulating ketopantoate levels and, in turn, regulating pantoate and/or pantothenate production in appropriately engineered microorganisms. To demonstrate this regulation, PA824 was grown in test tube cultures of SVY glucose plus 5 g/L β -alanine and \pm 5 g/L serine for 48 hours and
- 30 43°C.

Table 4: *Production of pantothenate and HMBPA by PA824 with and without the addition of serine*

serine added at 5 g/L	OD ₆₀₀	[pan] g/L	[HMBPA] g/L
-	16.3	4.9	0.84
-	14.0	4.5	0.80
+	13.1	6.4	0.56
+	12.9	6.0	0.62

5 As demonstrated by the data presented in Table 4, addition of serine increases the level of production of pantothenate (while conversely decreasing HMBPA production).

10 **Example III. Engineering bacterial cells with increased amounts of serine hydroxymethyl transferase, the *glyA* gene product.**

As an alternative to feeding serine, another method of increasing serine levels and/or serine utilization levels (and accordingly, methylenetetrahydrofolate levels) in order to regulate pantothenate production levels is to increase synthesis or the activity of 3-phosphoglycerate dehydrogenase or of serine hydroxymethyl transferase (the *serA* and *glyA* gene products, respectively), thereby increasing serine and methylenetetrahydrofolate biosynthesis in appropriately engineered microorganisms.

Expression of the *glyA* gene was increased by transforming *B. subtilis* cells with an expression cassette containing the *B. subtilis glyA* gene cloned downstream of a strong, constitutive promoter. To construct the expression cassette the primers RY417 and RY418 depicted in Table 5 were used to amplify the *glyA* gene by PCR from chromosomal DNA isolated from *B. subtilis* PY79.

Table 5: *Primers used in the amplification of *B. subtilis glyA* and *serA**

RY405	CCCTCTAGAGGAGGAGAAAACATGTTTCGAGTATTGGTC TCAGACAAAATG	SEQ ID NO:20
RY406	CCCGGATCCAATTATGGCAGATCAATGAGCTTCACAGAC ACAA	SEQ ID NO:21
RY417	GGATCTAGAGGAGGTGTAAACATGAAACATTTACCTGCG CAAGACGAA	SEQ ID NO:22
RY418	CGGGGATCCCCCATCAACAATTACACACTTCTATTGATT CTAC	SEQ ID NO:23

RY417 contains the RBS2 synthetic ribosome binding site just downstream from an *XbaI* site. The amplified DNA was then cut with *XbaI* and *BamHI* and cloned between the *XbaI* and *BamHI* sites in vector pAN004 (Figure 5) to yield plasmid pAN396 (Figure 6; SEQ ID NO:24). The pAN004 vector contains the phage SP01 P₂₆ promoter immediately upstream of the *XbaI* cloning site to drive expression of the cloned *glyA* gene. Just downstream of the expression cassette, pAN396 contains a *cat* gene that functions in *B. subtilis*. To transform *B. subtilis*, the *NotI* DNA fragment containing the P₂₆ *glyA* cassette and *cat* gene was isolated from pAN396, self-ligated, and transformed into competent cells of *B. subtilis* PY79. Several chloramphenicol resistant transformants were selected and named PA1007 and PA1008. Chromosomal DNA was isolated from each of these strains and used to transform competent cells of PA721B-39 and PA824 to yield strains PA1011 and PA1014, respectively. SDS polyacrylamide gel electrophoresis of cell extracts of selected isolates of PA1011 and PA1014 confirmed that these strains contained increased amounts of the *glyA* gene product as compared to their parent strains PA721B-39 (described in Example I) and PA824 (described in International Public. No. WO 01/21772). To test the effect of increasing *glyA* expression on pantothenate production, PA1011 and PA1014 were grown in test tube cultures of SVY glucose plus 5 g/L β -alanine at 43°C for 48 hours. As shown by the data presented in Table 6, PA1014 produced more pantothenate (4.5 g/L) than its parent strain PA824 (3.2 g/L). Similarly, PA1011 produced on average more pantothenate (4.35 g/L) than its parent strain PA721B-39 (4.05 g/L).

Table 6. Production of pantothenate and HMBPA by PA1011 and PA1014 compared to PA721B-39 and PA824.

Strain	OD ₆₀₀	Pantothenate g/L	HMBPA g/L
PA1014 #1	14	4.5	0.27
PA1014 #2	15	4.5	0.31
PA824	16	3.1	0.31
PA824	15	3.3	0.28
PA1011 #1	17	4.5	0.24
PA1011 #2	12	4.2	0.27
PA721B-39	18	4.0	0.22
PA721B-39	16	4.1	0.25

**Example IV. Engineering bacterial cells with increased amounts of
3-phosphoglycerate dehydrogenase, the *serA* gene product.**

The product of the *serA* gene, 3-phosphoglycerate dehydrogenase, is the first committed enzyme in the pathway to serine biosynthesis (see Figure 2). Since
5 serine is one of the substrates for the synthesis of MTF, we engineered the overexpression of the *serA* gene to increase serine levels in the cell. In a manner similar to that described above for the *glyA* gene in Example III, expression of the *serA* gene was increased by transforming *B. subtilis* cells with an expression cassette containing the
10 *B. subtilis serA* gene cloned downstream of a strong, constitutive promoter. To construct the expression cassette the primers RY405 and RY406 depicted in Table 5 were used to amplify the *serA* gene by PCR from chromosomal DNA isolated from *B. subtilis* PY79. The amplified DNA was then cut with *XbaI* and *BamHI* and cloned between the *XbaI* and *BamHI* sites in vector pAN004 (Figure 5) to yield plasmid pAN393 (Figure 7; SEQ ID NO:25). To transform *B. subtilis*, the *NotI* DNA fragment containing the *P₂₆ serA*
15 cassette and *cat* gene was isolated from pAN393, self-ligated, and transformed into competent cells of *B. subtilis* PY79. Several chloramphenicol resistant transformants were selected and named PA1004 and PA1005. Chromosomal DNA was isolated from each of these strains and used to transform competent cells of PA721B-39 and PA824 to yield strains PA1010 and PA1013, respectively. SDS polyacrylamide gel
20 electrophoresis of cell extracts of selected isolates of PA1010 and PA1013 confirmed that these strains contained increased amounts of the *serA* gene product as compared to their parent strains PA721B-39 and PA824.

To test the effect of increasing *serA* expression on pantothenate
25 production, PA1010 and PA1013 were grown in test tube cultures of SVY glucose plus 5 g/L β -alanine at 43°C for 48 hours. As shown by the data presented in Table 7, PA1010 produced on average more pantothenate (4.7 g/L) than its parent strain PA721B-39 (4.1 g/L). Similarly, PA1013 produced on average more pantothenate (4.1 g/L) than its parent strain PA824 (3.1 g/L).

30

Table 7. Production of pantothenate and HMBPA by PA1010 and PA1013 compared to PA721B-39 and PA824.

Strain	OD ₆₀₀	Pantothenate g/L	HMBPA g/L
PA1010 #3	16	4.8	0.23
PA1010 #5	15	4.5	0.26
PA1010 #6	22	4.7	0.24
PA721B-39	18	4.0	0.22
PA721B-39	16	4.1	0.25
PA1013 #2	14	3.3	0.25
PA1013 #4	14	4.2	0.28
PA1013 #5	16	5.5	0.37
PA1013 #8	13	3.6	0.24
PA824	17	3.0	0.27
PA824	16	3.1	0.29

Example V. Shake flask and fermentor experiments with strains with increased expression of *serA* and *glyA*.

Based on performance in test tubes, two strains with an amplifiable *serA* cassette and two strains with an amplifiable *glyA* cassette were selected, one each from two parents, PA824 and PA721B-39. The four strains were grown beside the parents in shake flasks (Table 8). In Soy flour MOPS Glucose (SMG) medium, all of the 4 strains produced more pantothenate than their parent strains. In Soy flour MOPS Maltose (SMM) medium one out of the four strains appeared superior to the parent strain.

The *serA* overexpressing strain and the *glyA* overexpressing strain from each parent were run simultaneously in 10-liter Chemap bench fermentors. The *glyA* overexpressing strain derived from PA824, PA1014-3, that had given the highest pantothenate titer in SMM, also performed the best in fermentors (Table 9). Strain PA1014-3 produced 71 g/l pantothenate in 36 hours in the culture supernatant and 86 g/l pantothenate in 48 hours in the culture supernatant compared to the parent PA824 which produced 41 g/l and 46 g/l pantothenate, respectively. The *serA* strain, PA1012-4, also produced significantly more pantothenate than the PA824 control in the culture supernatant, 52 g/l and 60 g/l at 36 and 48 hours, respectively. These results clearly demonstrate the effectiveness of increasing both *glyA* and *serA*.

The *serA* overexpressing and *glyA* overexpressing derivatives of PA721B-39 were clearly improved over their parent strain as well. Both produced about 80 g/l pantothenate (82 g/l and 79 g/l, respectively) in the culture supernatants in 48 hours. The effect of the increased PanB levels in the PA721B-39 derivatives versus the PA824 derivatives manifests itself in the reduction of HMBPA. PA721B-39 and its derivatives produce less HMBPA after 48 hours than PA824 or even PA668-24. Increasing GlyA also appears to lower the flow of carbon to HMBPA.

Table 8. Shake flask evaluation of pantothenate production strains overexpressing *serA* or *glyA*.

Carbon source	Strain	Added cassette	HMBPA (g/l)	Pantothenate (g/l)
Glucose	PA824		3.5	4.0
	PA1012-4	<i>serA</i>	3.0	4.6
	PA1014-3	<i>glyA</i>	2.5	4.7
	PA721B-39		0.9	5.0
	PA1010-6	<i>serA</i>	1.9	9.6
	PA1011-2	<i>glyA</i>	1.7	10.0
Maltose	PA824		1.2	10.4
	PA1012-4	<i>serA</i>	0.8	9.8
	PA1014-3	<i>glyA</i>	1.1	16.1
	PA721B-39		0.6	11.6
	PA1010-6	<i>serA</i>	0.5	10.2
	PA1011-2	<i>glyA</i>	0	10.3

All data are the average of duplicate shake flasks after 48 hours.

Conditions: 40ml medium / 200ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum and 43°C.

Medium: 20 g/l Cargill 200/20 soy flour, 1 x PSTE, 8 g/l (NH₄)₂SO₄ and 5g/l glutamate.

Buffer: 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2.

Carbon Source (Sterilized separately as 20 x stock): 60 g/l glucose or maltose w/ 10 mM Mg and 1.4 mM Ca.

Table 9. 10 liter fermentor evaluations of pantothenate production strains overexpressing *serA* or *glyA*.

run	Strain	Parent	Added cassette	HMBPA (g/l)		Pantothenate (g/l)	
				36 hrs	48 hrs	36 hrs	48 hrs
P285	PA824			18	25	41	46
P284	PA1012-4	PA824	<i>serA</i>	20	21	52	60
P286	PA1014-3	PA824	<i>glyA</i>	14	16	71	86
P259	PA721B-39			4	5	34	42
P287	PA1010-6	PA721B-39	<i>serA</i>	4	5	65	82
P289	PA1011-2	PA721B-39	<i>glyA</i>	2	3	56	79
P275	PA668-24	PA824		3	9	55	72

5

The medium used is PFM-222. It is the same as medium PFM-155 described in U.S. Ser. No. 60/262,995 (filed January 19, 2001) except for the following changes: (1) In the Batch Material: There is no Amberex 1003. Cargill 200/20 (soy flour) 40 g/L has been changed to Cargill 20-80 (soy grits) 50 g/L, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ is replaced with $\text{MgCl}_2 \cdot 7\text{H}_2\text{O}$, 1 g/L, and SM-1000X is replaced with PSTE-1000X (PSTE-1000X = $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$, 2.0 g/L; $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 1.5 g/L; $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$, 2.0 g/L; $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 0.25 g/L; $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$, 0.75 g/L). In the Feed Material: SM-1000X is replaced with PSTE-1000X

10

Increasing pantothenate production can also be achieved by combining overexpression of *serA* and *glyA* in a single strain, and/or by introducing a mutation that leads to feedback resistant *serA* or *glyA*, or both.

15

Example VI. Increasing the expression of the *glyA* gene by mutating the *purR* gene.

As described in Examples III and V, expression of the *glyA* gene can be increased by adding one or more copies of a cassette in which the *glyA* gene is driven by a strong, constitutive promoter. An alternative method to increase *glyA* expression is to alter its regulation. Literature describing a *glyA::lacZ* fusion suggests that the *glyA* promoter is of moderate strength under normal conditions (about 400 Miller Units), but that this promoter is capable of being induced to relatively high levels (1,800 Miller units) if its negative regulator, the *purR* gene, is deleted (Saxild *et al.* (2001) *J. Bacteriol.* 183:6175-6183). Therefore, experiments were performed to determine if *glyA*

20

25

expression, and consequently pantothenate production, could be increased by deleting *purR* from a pantothenate production strain.

The *B. subtilis purR* gene was amplified from PY79 chromosomal DNA by PCR, and the resulting fragment was cloned into PvuII cleaved pGEM5-Zf(+) vector DNA to give plasmid pAN835F (SEQ ID NO:26, Figure 8). This step eliminated the PvuII sites at both ends of the insert, leaving a unique PvuII site in the middle of the *purR* open reading frame. Next, a blunt PCR DNA fragment containing the Gram positive kanamycin resistance gene from pAN363F (SEQ ID NO:27) was ligated into this unique PvuII site of pAN835F to give pAN838F (SEQ ID NO:28, Figure 9).

pAN838F was then transformed into PY79, PA668-24, and PA824, selecting for kanamycin resistance at 10 mg/l to give new sets of strains named PA1059, PA1060, and PA1061, respectively. It was shown by PCR that all new isolates contained the disrupted *purR::kan* allele that was expected from a double crossover event. Several isolates of PA1060 and PA1061 were tested for pantothenate production in test tube cultures grown in SVY glucose plus β -alanine (Table 9). The best isolates derived from PA668-24, PA1060-2 and PA1060-4, gave an improvement from 3.0 g/l pantothenate to 5.3 to 5.1 g/l, respectively, which is an increase of 75%. Likewise, the best isolates derived from PA824, PA1061-1 and PA1061-2 gave an increase from about 3.1 g/l to 5.4 g/l, also a 75% gain. These results suggest that the *glyA* gene is substantially induced in these new strains by disruption of the *purR* gene. Alternatively, the improvements in pantothenate production in PA1060 and PA1061 may be due to more complex pleiotropic effects. In either case, deregulation of the *purR* regulon has a positive effect on pantothenate production.

In other embodiments, the *purR* disruption can be installed in other pantothenate production strains, for example those that have an integrated *P₂₆serA* allele or more than one copy of the *P₂₆panBCD* operon. The *purR* gene can also be used as a site for addition of desired expression cassettes, such as *P₂₆panB*. One can also use resistance to the guanine analogs, such as 8-azaguanine, as a selection for a *purR* mutation.

Table 10. Production of pantothenate and fantothenate by derivatives of PA824 and PA668-24 containing disrupted *purR*, in test tube cultures grown in SVY glucose plus 5 g/l β -alanine.

Strain	inoculum*	parent	new feature	OD ₆₀₀	[fan] g/l	[pan] g/l
PA668-24	cam 5, tet 7.5	PA824	-	9	b.d.	3.0
"	"	"	-	12	b.d.	3.0
PA1060-1	cam 5, tet 7.5	PA668-24	<i>purR::kan</i>	14	0.14	4.5
PA1060-2	"	"	"	12	b.d.	5.3
PA1060-3	"	"	"	12	b.d.	4.5
PA1060-4	"	"	"	16	0.11	5.1
PA824	tet 30	PA377	-	9	0.25	3.2
"	"	"	-	11	0.22	3.0
PA1061-1	tet 15	PA824	<i>purR::kan</i>	13	0.45	5.4
PA1061-3	"	"	"	14	0.39	5.4
PA1061-4	"	"	"	11	0.40	4.7

b.d. = below detection

* Concentration of antibiotics in the petri plate from which the inoculum colony was taken.

Example VII. Overexpression of the *serA* gene from a non-amplifiable cassette.

This Example describes another method to increase serine production, in which a two step procedure deposits a strong, constitutive promoter (*P*₂₆) in front of the chromosomal *serA* gene. Two plasmids were constructed, each containing about 700 base pairs of DNA sequence from the region immediately upstream of the native *serA* gene. The first plasmid, pAN821, also contains the 3' half of the *serA* coding region, and in between the two aforementioned sequences, a kanamycin resistance gene (SEQ ID NO:30, Figure 10). When transformed into *B. subtilis*, selecting for kanamycin resistance, pAN821 will give a disruption of the *serA* gene, leading to serine auxotrophy. This creates a genetic sequence termed the $\Delta serA::kan$ allele.

The second plasmid, designed to introduce the *P*₂₆ *serA* structure, was constructed by inserting the *serA* upstream sequence at the 5' end of the *P*₂₆ promoter in pAN395. The resulting plasmid, pAN824, is shown in Figure 11 (SEQ ID NO:31). The plasmid pAN395 is similar to pAN393 described in Example IV. The open reading frame of the *serA* gene was synthesized by PCR using *B. subtilis* PY79 DNA as the template. The upstream primer contains an *Xba*I site and a moderately strong synthetic ribosome binding site, RBS2. The downstream primer contains a *Bam*HI site. This *serA* open reading frame was used to replace the *panBCD* genes in the medium copy plasmid, pAN006, to give pAN395 (SEQ ID NO:29, Figure 12). This plasmid contains the *serA* gene expressed from the *P*₂₆ promoter and the RBS2 ribosome binding site.

The $\Delta serA::kan$ allele from pAN821 was introduced into strain PA824 to give PA1026. As expected, PA1026 did not grow on minimal medium. In the second step, the *P*₂₆ *serA* cassette from plasmid pAN824 was introduced into PA1026, selecting for serine prototrophy, to give strain PA1028. Several PA1028 isolates were confirmed to have the expected chromosomal structure (*P*₂₆ *serA*) by diagnostic PCR. These isolates were then tested for pantothenate production in test tube cultures grown for 48 hours in SVY plus 5 g/l β -alanine (Table 11). The PA1028 isolates (derived from PA824) gave increases from 10% to 25% in pantothenate production. As shown in Table 12, in shake flask experiments, PA824 produced about 7 g/l pantothenate, whereas PA1028 produced 11 g/l.

Example VIII. Construction of pantothenate producing strains that contain both an integrated non-amplifiable P_{26} *serA* cassette and an amplifiable P_{26} *glyA* cassette.

5 Since a non-amplifiable P_{26} *serA* cassette integrated at *serA* led to higher pantothenate synthesis (see, *e.g.*, Table 12), and since a chloramphenicol amplifiable P_{26} *glyA* cassette at *glyA* led to much higher pantothenate synthesis (see, *e.g.*, PA1014-3, Table 8), it was proposed that a combination of the two might be synergistic. Strain PA1028-4, which is the derivative of PA824 that contains the non-amplifiable P_{26} *serA* cassette integrated at *serA*, was transformed to chloramphenicol resistance at 5 mg/l using chromosomal DNA from PA1014-3, to give a set of strains named PA1038, which now contain the chloramphenicol amplifiable P_{26} *glyA* cassette. PA1038 isolates were tested for pantothenate production using standard test tube cultures grown in SVY plus β -alanine (Table 13). As expected, PA1038 showed a dramatic increase in pantothenate production from about 4.2 g/l by PA824 to 6.6 to 7.5 g/l by the PA1038 set. Isolates PA1038-3 and PA1038-12 were further tested in shake flasks as shown in Table 12. Both produced an average of 13.6 g/l pantothenate, as compared to the 7.4 g/l pantothenate produced by PA824.

20 **Table 11. Production of pantothenate and fantothenate by derivatives of PA824 that contain a single copy of P_{26} *serA* at the *serA* locus, in 48 hour test tube cultures grown in SVY plus 5 g/l β -alanine.**

Strain	parent	OD ₆₀₀	[fan] g/l	[pan] g/l
PA824		17	0.44	4.0
PA824		15	0.45	4.0
PA1028-1	PA824	13	0.46	4.4
PA1028-2	"	18	0.49	4.9
PA1028-3	"	15	0.44	4.4
PA1028-4	"	13	0.43	4.5
PA1028-5	"	14	0.45	4.4
PA1028-6	"	11	0.43	4.8
PA1028-8	"	15	0.51	5.0

25

b.d. = below detection

Table 12. Shake flask evaluation of pantothenate production strains overexpressing *serA* and/or *glyA*.

Strain	Parent	<i>glyA</i> cassette	<i>serA</i> cassette	Pantothenate (g/l)	Pantothenate (g/l)
PA824				0.6	7.4
PA1014-3	PA824	N x P ₂₆ <i>glyA</i>		0.7	12.0
PA1028-4	PA824		P ₂₆ <i>serA</i> @ <i>serA</i>	0.8	11.1
PA1038-3	PA1028-4	N x P ₂₆ <i>glyA</i>	P ₂₆ <i>serA</i> @ <i>serA</i>	0.5	13.6
PA1038-12	PA1028-4	N x P ₂₆ <i>glyA</i>	P ₂₆ <i>serA</i> @ <i>serA</i>	0.6	13.6

All data are the average of duplicate shake flasks after 48 hours.

Conditions: 40 ml medium / 200 ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum and 43°C.

Inoculum: SVY base w/maltose 24 hours at 43°C.

Medium: 20 g/l Cargill 200/20 soy flour, 8 g/l (NH₄)₂SO₄, 5g/l glutamate and 1x PSTE.

Buffer: 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2.

Carbon Source (Sterilized separately as 20X stock): 30 g/l maltose, 5 mM MgCl₂ and 0.7 mM CaCl₂.

Table 13. Pantothenate production by PA1038, a derivative of PA824 that contains a non-amplifiable P₂₆ serA cassette at serA and an amplifiable P₂₆ glyA cassette at glyA.

5

Strain	Inoculum Medium	OD ₆₀₀	[Fan] g/L	[Pan] g/L
PA824	tet 15	16	0.56	4.4
PA824	"	14	0.59	4.3
PA824	tet 30	12	0.57	4.3
PA824	"	14	0.58	4.2
PA1038-3	cam 5, tet 15	16	0.47	7.2
PA1038-4	"	14	0.49	7.0
PA1038-5	"	15	0.52	7.0
PA1038-6	"	15	0.51	7.2
PA1038-9	"	14	0.56	7.2
PA1038-11	"	13	0.49	6.6
PA1038-12	"	16	0.58	7.5

Test tube cultures were grown with SVY glucose plus 5 g/l β -alanine at 43°C for 48 hours.

10

Example IX. Increasing the production of MTF by altering the glycine cleavage pathway.

As demonstrated with the above examples, increasing MTF production in bacteria increases the production of pantothenate in strains that have been engineered to produce more pantothenate by manipulation of the *panBCD* and/or *panE* genes. It has been demonstrated that pantothenate production can be increased by increasing the expression of the *glyA* or the *serA* gene. Stronger promoters or ribosome binding sites can be used to increase *glyA* or *serA* expression as demonstrated in Examples III through V and VII through VIII. Alternatively, the expression of the *glyA* gene can be deregulated in *Bacillus* by disrupting the *purR* repressor gene as illustrated in Example VI.

Another method to increase MTF production is to enhance the expression of enzymes of the glycine cleavage pathway. For example, enzymes encoded by the *gcvT*, *gcvPA*, *gcvPB*, *gcvH*, and *pdhD* genes catalyze the breakdown of glycine to MTF, CO₂, and NH₃. A strong, constitutive promoter, such as the SP01 phage P₂₆ promoter described previously, can be cloned in front of the *gcvT-gcvPA-gcvPB* operon or in front of the *gcvH* or *pdhD* gene to enhance their expression. In addition to the above

mentioned approaches, additional glycine, which is inexpensive, can be added to the medium to further enhance MTF production by any strain engineered as described herein.

5

Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

10

What is claimed:

1. A process for the enhanced production of pantothenate, comprising culturing a microorganism having a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, under conditions such that pantothenate production is enhanced.
2. A process for the enhanced production of pantothenate, comprising culturing a microorganism having
 - (i) a deregulated pantothenate biosynthetic pathway, and
 - (ii) a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway,under conditions such that pantothenate production is enhanced.
3. The process of claim 2, wherein said microorganism has at least two pantothenate biosynthetic enzymes deregulated.
4. The process of claim 2, wherein said microorganism has at least three pantothenate biosynthetic enzymes deregulated.
5. The process of claim 2, wherein said microorganism has at least four pantothenate biosynthetic enzymes deregulated.
6. The process of claim 5, wherein said microorganism has a deregulated ketopantoate hydroxymethyltransferase, a deregualted ketopantoate reductase, a deregulated pantothenate synthetase and a deregulated aspartate- α -decarboxylase.
7. The process of any one of claims 1 to 6, wherein said microorganism further has a deregulated isoleucine-valine (*ilv*) biosynthetic pathway.
8. The process of claim 7, wherein said microorganism has at least two isoleucine-valine (*ilv*) biosynthetic enzymes deregulated.
9. The process of claim 7, wherein said microorganism has at least three isoleucine-valine (*ilv*) biosynthetic enzymes deregulated.

10. The process of claim 9, wherein said microorganism has a deregulated acetohydroxyacid synthetase, a deregulated acetohydroxyacid isomeroreductase, and a deregulated dihydroxyacid dehydratase.

5 11. The process of any one of claims 1 to 10, wherein the microorganism has at least one MTF biosynthetic enzyme deregulated.

12. The process of claim 11, wherein the microorganism has a deregulated *glyA* gene.

10

13. The process of claim 11, wherein the microorganism has a deregulated *serA* gene.

14. The process of claim 11, wherein the microorganism has a
15 deregulated *glyA* gene and a deregulated *serA* gene.

15. The process of claim 12 or 14, wherein the microorganism has a mutated, deleted or disrupted *purR* gene.

20 16. A process for the enhanced production pantothenate, comprising culturing a microorganism having a deregualted pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway deregulated, such that production of pantothenate is enhanced.

25

17. A process for the production pantothenate, comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, such that at least 50 g/L
30 pantothenate is produced after 36 hours of culturing the microorganism.

18. The process of claim 17, comprising culturing the microorganism such that at least 60 g/L pantothenate is produced after 36 hours of culturing the microorganism.

35

19. The process of claim 17, comprising culturing the microorganism such that at least 70 g/L pantothenate is produced after 36 hours of culturing the microorganism.

20. A process for the production pantothenate, comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway deregulated, such that at least 60 g/L pantothenate is produced after 48 hours of culturing the microorganism.

21. The process of claim 20, comprising culturing the microorganism such that at least 70 g/L pantothenate is produced after 48 hours of culturing the microorganism.

22. The process of claim 20, comprising culturing the microorganism such that at least 80 g/L pantothenate is produced after 48 hours of culturing the microorganism.

23. The process of any one of the preceding claims, wherein pantothenate production is further enhanced by regulating pantothenate kinase activity.

24. The process of claim 23, wherein pantothenate kinase activity is decreased.

25. The process of claim 24, wherein CoaA is deleted and CoaX is downregulated.

26. The process of claim 24, wherein CoaX is deleted and CoaA is downregulated.

27. The process of claim 24, wherein CoaX and CoaA are downregulated.

28. The process of any one of the above claims, wherein said microorganism is cultured under conditions of excess serine.

29. A process for producing pantothenate comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway under conditions of excess serine, such that pantothenate is produced.

30. The process of any one of the above claims, wherein said microorganism has the pantothenate biosynthetic pathway deregulated such that pantothenate production is independent of β -alanine feed.
- 5 31. The process of any one of the above claims wherein the microorganism is a Gram positive microorganism.
32. The process of any one of the above claims wherein the microorganism belongs to the genus *Bacillus*.
- 10 33. The process of any one of the above claims, wherein the microorganism is *Bacillus subtilis*.
34. A product synthesized according to the process of any one of the above claims.
- 15 35. A composition comprising pantothenate produced according to the process of any one of the above claims.
- 20 36. A recombinant microorganism for the enhanced production of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway.
37. A recombinant microorganism for the enhanced production of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, and a deregulated isoleucine-valine (*ilv*) pathway.
- 25 38. The microorganism of claim 36 or 37, further having reduced pantothenate kinase activity.
- 30 39. The microorganism of any one of claims 36-38 which is a Gram positive microorganism.
- 35 40. The microorganism of any one of claims 36-38 belonging to the genus *Bacillus*.

41. The microorganism of any one of claims 36-38 which is *Bacillus subtilis*.

42. A process for producing pantothenate comprising culturing a
5 recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) at least one deregulated isoleucine-valine (*ilv*) biosynthetic enzyme-encoding gene;

10 under conditions such that at least 30 g/l pantothenate is produced after 36 hours of culturing the microorganism.

43. The process of claim 42, wherein said microorganism further has a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway and said
15 microorganism is cultured under conditions such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

44. A process for producing pantothenate comprising culturing a
recombinant microorganism having:

- 20
- (a) a deregulated *panB* gene; and
 - (b) a deregulated *panD* gene;

under conditions of excess serine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

25 45. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a deregulated methylenetetrahydrofolate (MTF) biosynthetic
30 pathway;

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

46. A process for producing pantothenate comprising culturing a
35 recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a deregulated *glyA* gene;

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

47. A process for producing pantothenate comprising culturing a
5 recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a mutated, deleted or disrupted *purR* gene;

under conditions of excess valine, such that at least 50 g/l pantothenate is
10 produced after 36 hours of culturing the microorganism.

48. A process for producing pantothenate comprising culturing a
recombinant microorganism having:

- (a) a deregulated *panB* gene;
- 15 (b) a deregulated *panD* gene; and
- (c) a deregulated *serA* gene;

under conditions of excess valine, such that at least 50 g/l pantothenate is
produced after 36 hours of culturing the microorganism.

20 49. A process for producing pantothenate comprising culturing a
recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene;
- (c) a deregulated *serA* gene;
- 25 (d) a deregulated *glyA* gene; and

under conditions of excess valine, such that at least 50 g/l pantothenate is
produced after 36 hours of culturing the microorganism.

leucine

α -KIC

β -IPM

α -IPM

2 x pyruvate

acetohydroxyacid synthetase *ilvBN*

acetolactate

acetohydroxyacid isomerase *ilvC*

α, β -DHIV

ilvD

valine

α -KIV

leuA

leuCD

leuB

panB

ketopantoate

ketopantoate hydroxymethyltransferase

ketopantoate

panE1

ketopantoate reductase

pantoate

panD

aspartate \rightarrow β -alanine

aspartate- α -decarboxylase

panC

pantothenate synthetase

pantothenate

FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11





Fig. 12



SEQUENCE LISTING

<110> OmniGene BioProducts, Inc. et al.

<120> MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF
PANTOTHENATE

<130> BGI-154PC

<160> 31

<170> PatentIn Ver. 2.0

<210> 1

<211> 194

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter
sequence

<220>

<221> -35_signal

<222> (136)..(141)

<220>

<221> -10_signal

<222> (159)..(164)

<400> 1

gctattgacg acagctatgg ttcactgtcc accaaccaaa actgtgctca gtaccgccaa 60
tattttctccc ttgaggggta caaagagggtg tccctagaag agatccacgc tgtgtaaaaa 120
ttttacaaaa aggtattgac tttccctaca ggggtgtgtaa taatttaatt acaggcgggg 180
gcaaccccg cgtg 194

<210> 2

<211> 163

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter
sequence

<220>

<221> -35_signal

<222> (113)..(118)

<220>

<221> -10_signal

<222> (136)..(141)

<400> 2

gcctacctag cttccaagaa agatataccta acagcacaag agcggaaaga tgttttgttc 60
tacatccaga acaacctctg ctaaaattcc tgaaaaattt tgcaaaaagt tgttgacttt 120

atctacaagg tgtggtataa taatcttaac aacagcagga cgc

163

<210> 3

<211> 127

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter
sequence

<220>

<221> -35_signal

<222> (34)..(39)

<220>

<221> -10_signal

<222> (58)..(63)

<220>

<221> -35_signal

<222> (75)..(80)

<220>

<221> -10_signal

<222> (98)..(103)

<400> 3

gaggaatcat agaattttgt caaaataatt ttattgacaa cgtcttatta acgttgatat 60
aatttaaatt ttatttgaca aaaatgggct cgtgtgttac aataaatgta gtgagggtgga 120
tgcaatg 127

<210> 4

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome
binding site

<400> 4

taaacatgag gaggagaaaa catg

24

<210> 5

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome
binding site

<400> 5

attcgagaaa tggagagaat ataatatg

28

<210> 6

<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 6
agaaaggagg tga

13

<210> 7
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<221> misc_feature
<222> 17, 18, 19, 20
<223> n = a, t, c, or g

<400> 7
ttaagaaagg aggtgannnn atg

23

<210> 8
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<221> misc_feature
<222> 16, 17, 18, 19, 20
<223> n = a, c, t, or g

<400> 8
ttagaaagga ggtgannnnn atg

23

<210> 9
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<221> misc_feature
<222> 14, 15, 16, 17, 18, 19, 20
<223> n = a, c, t, or g

<400> 9
agaaaggagg tgannnnnnn atg 23

<210> 10
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<221> misc_feature
<222> 14, 15, 16, 17, 18, 19
<223> n = a, c, t, or g

<400> 10
agaaaggagg tgannnnnna tg 22

<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 11
ccctctagaa ggaggagaaa acatg 25

<210> 12
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 12
ccctctagag gaggagaaaa catg 24

<210> 13
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 13
ttagaaagga ggattttaa atg 23

<210> 14
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome
binding site

<400> 14

ttagaaagga ggtttaatta atg

23

<210> 15

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome
binding site

<400> 15

ttagaaagga ggtgatttaa atg

23

<210> 16

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome
binding site

<400> 16

ttagaaagga ggtgtttaaa atg

23

<210> 17

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome
binding site

<400> 17

attcgagaaa ggaggtgaat ataatatg

28

<210> 18

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome
binding site

<400> 18

attcgagaaa ggaggtgaat aataatg

27

<210> 19

<211> 28

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 19
attcgtagaa aggaggtgaa ttaatatg 28

<210> 20
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:5' PCR primer
<223> for serA gene

<400> 20
ccctctagag gaggagaaaa catgtttcga gtattggtct cagacaaaat g 51

<210> 21
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:3' PCR primer
<223> for serA gene

<400> 21
cccggatcca attatggcag atcaatgagc ttcacagaca caa 43

<210> 22
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:5' PCR primer
<223> for glyA gene

<400> 22
ggatctagag gaggtgtaaa catgaaacat ttacctgcgc aagacgaa 48

<210> 23
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:3' PCR primer
<223> for glyA gene

<400> 23
cggggatccc ccatcaacaa ttacacactt ctattgattc tac 43

<210> 24

<211> 7926

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:serA overexpression

<223> plasmid

<400> 24

```
gaattttgcg gccgcttcga aagctgtaat ataaaaacct tcttcaacta acggggcagg 60
ttagtgacat tagaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 120
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaacaat cctgcatgat 180
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacctt 240
tattaatgaa ttttcctgct gtaataatgg gtagaaggta attactatta ttattgatat 300
ttaagttaaa ccagtaaat gaagtccatg gaataataga aagagaaaaa gcatttttcag 360
gtataggtgt tttgggaaac aatttccccg aaccattata tttctctaca tcagaaaagg 420
ataaatcata aaactctttg aagtcattct ttacaggagt ccaaatacca gagaatgttt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atccaataa cctaactctc 540
cgtcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 600
aaataaatgc agggtaaaat ttatatcctt ctgtgtttat gtttcgggtat aaaacactaa 660
tatcaatttc tgtggttata ctaaaagtcg ttgtgtggtt caaataatga ttaaatatct 720
cttttctctt ccaattgtct aaatcaattt tattaaagtt catttgatat gcctcctaaa 780
tttttatcta aagtgaattt aggaggctta ctgtgtctgt ttcttcatta gaatcaatcc 840
ttttttaaaa gtcaatatta ctgtaacata aatatatatt ttaaaaaatat ccacttttat 900
ccaattttcg tttgttgaac taatgggtgc ttagttgaa gaataaagac cacattaaaa 960
aatgtggtct tttgtgtttt tttaaaggat ttgagcgtag cgaaaaatcc ttttctttct 1020
tatcttgata ataagggtaa ctattgaatt cggtagcaag agtttgtaga aacgcaaaaa 1080
ggccatccgt caggatggcc ttctgcttaa ttgatgcct ggcagtttat ggcgggcgtc 1140
ctgcccgcga cctccgggc cgttgcctcg caacgttcaa atccgctccc ggcggatttg 1200
tcctactcag gagagcgttc accgacaaac aacagataaa acgaaaggcc cagtctttcg 1260
actgagcctt tcgttttatt tgatgcctgg cagttcccta ctctcgcatg gggagacccc 1320
acactaccat cggcgctacg gcgtttcact tctgagttcg gcatggggtc aggtgggacc 1380
accgcgctac tgccgccagg caaattctgt ttatcagac cgcttctgcg ttctgattta 1440
atctgtatca ggctgaaaat cttctctcat ccgccaaaac aggatccaat tatggcagat 1500
caatgagctt cacagacaca atatcaggga catttgtag ttctttcaca attttatctt 1560
ccagatgtct gtcaaaggaa agcatcatga tggcttctcc gcctttttcc ttacggccaa 1620
cctgcatagt tgcaatgtta atatcattat ctccgagaat acgtcctact cggccgatga 1680
cacctgttgt atcttgatgc tggatataca ccaagtgacc agtcggataa aaatcaatat 1740
taaatccatt gatctcgaca attcgttctc cgaaatgagg aatatacgta gccgttacag 1800
taaagggtgt gcggtctcct gtcactttta cgctgatgca gttatcgtat ccagattcag 1860
aagaggaaat tttttcactg aagctaattg cgcttctttt tgcgacaccc ccggcattga 1920
cctcattaac agtagagtct acgcgcggtt ttaaaaagcc tgacagaagg gcttttgtaa 1980
tgaacgatgt ttcaagttta gcaattgtgc cttcatattg aatggcaaca tcctgtactg 2040
gttctttcat gcactgtgat acaaggctgc caatttttcc tgcaatttga tggtaaggct 2100
taatttttagc aaattcatct tttgtcatgg caggcagggt gatagctgac atgacaggca 2160
ggccttttgc gaactgcaga acttcttctg acacttgggc ggcgacattg agctgtgctt 2220
cttcgttga tgctcccaag tgaggagtgg caatgactaa tggatgatca acaagtttgt 2280
tgtcaactgg cgggttcgact tcgaaaacgt caagcgctgc tcccgcacaa tgcccgtttt 2340
ccaaagcttc gagaagtgtc gcttcatcga taattccgcc tcgcgcacag ttaattaagc 2400
gaacgccttt tttcgttttt gcaatcgttt ctttattcaa taagcctttt gtttcttttg 2460
ttaaaggcgt gtgaacggta atgatatacg cactttcaag cacttcttca aatgtacggc 2520
tgtttacgcc gatttttttc gctctttctt ccgttaagaa aggatcaaaa acgtgcacag 2580
tcataccgaa cgctcctcga cgctgtgcaa tttcacttcc gattcggcct aatcctacaa 2640
taccaagcgt ttttcataaa agctctgaac cgacataagc tgtcggttc cactctctgg 2700
atttactga gatattagcc tgcggaatgt gtctcattaa agaagagatc attgcaaag 2760
tatgtcagc tgcgaaatg gtgttgccgt tcggagcatt gatcacgatt acccctgtgt 2820
tcgtagcctc atcaatatcg atattatcga caccgacacc ggctcttccg acaattttta 2880
aagaagtcatt tttgttgaaa aggtcttctg ttacttttgt cgcgcttcgc accaaaagag 2940
catcaaaagt atgtaattca tcttctgcat ctgctacgtt tttttgaacg atttcaataa 3000
```

```

agtctgattc aataagtggc tgtaaaccgt cgttgctcat tttgtctgag accaatactc 3060
gaaacatgtt ttctcctcct ctagagcgctc ctgctgttgt taagattatt ataccacacc 3120
ttgtagataa agtcaacaac tttttgcaaa atttttcagg aatttttagca gaggttggtc 3180
tgatgtaga acaaaacatc tttccgctct tgtgctgtta ggatatcttt cttggaagct 3240
aggtaggcct cgagttatgg cagttgggta aaaggaaaca aaaagaccgt tttcacacaa 3300
aacggctctt ttcgattttct ttttacagtc acagccactt ttgcaaaaac cggacagctt 3360
catgccttat aactgctgtt tcggtcgaca agcttcgcga agcggccgca aaattcactg 3420
gccgtcgttt tacaacgtcg tgactgggaa aacctggcg ttaccaact taatcgctt 3480
gcagcacatc cccctttcgc cagctggcgt aatagcgaag aggccgcac cgatcgccct 3540
tccaacagt tgccgagcct gaatggcgaa tggcgctga tgcggtattt tctccttacg 3600
catctgtgag gtatttcaca ccgcatatgg acactctca gtacaatctg ctctgatgcc 3660
gcatagttaa gccagccccg acacccgcc aacctgctg actatgcttg taaaccgttt 3720
tgtgaaaaaa tttttaaaat aaaaaagggg acctctaggg tccccaatta attagtaata 3780
taatctatta aaggtcattc aaaaggtcat ccaccggtc agcttagtaa agccctcgct 3840
agattttaat gcggatgttg cgattacttc gccactatt gcgataacaa gaaaaagcca 3900
gcctttcatg atatatctcc caatttgtgt agggcttatt atgcacgctt aaaaataata 3960
aaagcagact tgacctgata gtttggctgt gagcaattat gtgcttagtg catctaacgc 4020
ttgagttaag ccgcgccgag aagcggcgct ggcttgaacg aattgttaga cattatttgc 4080
cgactacctt ggtgatctcg cttttcacgt agtggaacaa ttcttccaac tgatctgcgc 4140
gcgaggccaa gcgatcttct tcttgtccaa gataagcctg tctagcttca agtatgacgg 4200
gctgatactg ggccggcagg cgctccattg cccagtcggc agcgacatcc ttcggcgcg 4260
ttttgccggt tactgcgctg taccaaatgc gggacaacgt aagcactaca tttcgctcat 4320
cgccagccca gtccggcggc gagttccata gcgttaaggt ttcatttagc gcctcaaata 4380
gatectgttc aggaaccgga tcaaagagtt cctccgcgc tggacctacc aaggcaacgc 4440
tatgttctct tgcttttgtc agcaagatag ccagatcaat gtcgatcgtg gctggctcga 4500
agatacctgc aagaatgtca ttgcgtgccc attctccaaa ttgcagttcg cgcttagctg 4560
gataacgcca cggaatgatg tcgtcgtgca caacaatggt gacttctaca gcgcggagaa 4620
tctcgtcttc tccaggggaa gccgaagttt ccaaaaggtc gttgatcaaa gctcgccgcg 4680
ttgtttcatc aagccttacg gtcaccgtaa ccagcaaatc aatatcactg tgtggcttca 4740
ggccgccatc cactgcggag ccgtacaagt gtacggccag caacgtcgg tccagattgc 4800
gctcgatgac gccaaactacc tctgatagtt gagtcgatac ttcggcgatc accgcttccc 4860
tcatgatgtt taactttgtt ttagggcgac tgccctgctg cgtaacatcg ttgctgctcc 4920
ataacatcaa acatcgaccc acggcgtaac gcgcttgctg cttggatgcc cgaggcatag 4980
actgtacccc aaaaaaacag tcataacaag ccatgaaaac cgccactgcg ccgttaccac 5040
cgctgcgttc ggtcaagggt ctggaccagt tgcgtgagcg catacgctac ttgcattaca 5100
gcttacgaac cgaacaggct tatgtccact gggttcgtgc cttcatccgt ttccacgggt 5160
tgctgacccc ggcaaccttg ggcagcagcg aagtcgaggc atttctgtcc tggctggcga 5220
acgagcgcaa ggtttcgggt tccacgcac gtcaggcatt ggcggccttg ctgttcttct 5280
acggcaagggt gctgtgcacg gatctgccct ggcttcagga gatcggaaga cctcggccgt 5340
cgcgccgctt gccggtgggt ctgaccccg atgaagtgg tgcacccctc ggttttctgg 5400
aaggcgagca tcgtttgttc gccagcttc tgtatggaac gggcatgcgg atcagtgagg 5460
gtttgcaact gcgggtcaag gatctggatt tcgatcacgg cacgatcatc gtgcgggagg 5520
gcaagggtc caaggatcgg gccttgatgt taccgagag cttggcacc agcctgcgcg 5580
agcaggggaa ttgatccggt ggatgacctt ttgaatgacc tttaatagat tatattacta 5640
attaattggg gaccttagag gtcccctttt ttattttaaa aattttttca caaaacggtt 5700
tacaagcata acgggttttg ctgcccgcaa acgggctgtt ctggtgttgc tagtttgta 5760
tcagaatcgc agatccgggt tcagggttgc cggctgcaag cgctatttct tccagaattg 5820
ccatgatttt tccccacgg gagcgtcac tggctcccgt gttgtcggca gcttgattc 5880
gataagcagc atcgctgtt tcaggctgtc tatgtgtgac tgttgagctg taacaagttg 5940
tctcaggtgt tcaatttcat gttctagtgt ctttgtttta ctggtttcac ctgttctatt 6000
aggtgttaca tgctgttcat ctgttacatt gtcgatctgt tcatggtgaa cagctttaaa 6060
tgcacaaaaa actcgtaaaa gctctgatgt atctatcttt tttacaccgt tttcatctgt 6120
gcatatggac agttttccct ttgatatac acggtgaaca gttgttctac ttttgtttgt 6180
tagtcttgat gcttactga tagatacaag agccataaga acctcagatc cttccgtatt 6240
tagccagtat gttctctagt gtggttcgtt gtttttgcgt gagccatgag aacgaaccat 6300
tgagatcatg cttactttgc atgtcactca aaaattttgc ctcaaaactg gtgagctgaa 6360
tttttcagat taaagcatcg tgtagtgtt ttcttagtcc gttacgtagg taggaatctg 6420
atgtaatggt tgttggtatt ttgtcaccat tcatttttat ctggttggtc tcaagttcgg 6480
ttacgagatc catttgtcta tctagttaa cttggaaaat caacgtatca gtcgggcggc 6540

```

```

ctcgcttatac aaccaccaat ttcatattgc tgtaagtgtt taaatcttta cttattgggtt 6600
tcaaaaccca ttggttaagc cttttaaact catggtagtt attttcaagc attaacatga 6660
acttaaattc atcaaggcta atctctatat ttgccttggtg agttttcttt tgtggttagtt 6720
cttttaataa ccaactcataa atcctcatag agtatttggtt ttcaaaagac ttaacatggtt 6780
ccagattata ttttatgaat ttttttaact ggaaaagata aggcaatatc tcttcactaa 6840
aaactaattc taatttttcg cttgagaact tggcatagtt tgtccactgg aaaatctcaa 6900
agcctttaac caaaggattc ctgatttcca cagttctcgt catcagctct ctgggttgctt 6960
tagctaatac accataagca ttttccctac tgatgttcat catctgagcg tattggttat 7020
aagtgaacga taccgtccgt tctttccttg tagggttttc aatcgtgggg ttgagtagtg 7080
ccacacagca taaaattagc ttggtttcat gctcogttaa gtcatagcga ctaatcgcta 7140
gttcatttgc tttgaaaaca actaattcag acatacatct caattgggtct aggtgatttt 7200
aatcactata ccaattgaga tgggctagtc aatgataatt actagtcctt ttcctttgag 7260
ttgtgggtat ctgtaaattc tgctagacct ttgctggaaa acttgtaaat tctgctagac 7320
cctctgtaaa ttccgctaga cctttgtgtg ttttttttgt ttatattcaa gtgggtataa 7380
tttatagaat aaagaaagaa taaaaaaaga taaaaagaat agatcccagc cctgtgtata 7440
actcactact ttagtcagtt ccgcagtatt acaaaaggat gtcgcaaacg ctgtttgctc 7500
ctctacaaaa cagaccttaa aaccctaaag gcttaagtag caccctcgca agctcgggca 7560
aatcgtgaa tattcctttt gtctccgacc atcaggcacc tgagtcgctg tctttttcgt 7620
gacattcagt tcgctgcgct cacggctctg gcagtgaatg ggggtaaatg gcactacagg 7680
cgctttttat ggattcatgc aaggaaacta ccataatac aagaaaagcc cgtcacgggc 7740
ttctcagggc gttttatggc gggctctgcta tgtggtgcta tctgactttt tgctgttcag 7800
cagttcctgc cctctgattt tccagtctga ccacttcgga ttatcccggtg acaggtoatt 7860
cagactggct aatgcaccca gtaaggcagc ggtatcatca acaggcttac ccgtcttact 7920
gtcaac 7926

```

<210> 25

<211> 7701

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:glyA overexpression

<223> plasmid

<400> 25

```

gaatttttgcg gccgcttcga aagctgtaat ataaaaacct tcttcaacta acgggggcagg 60
ttagtgacat tagaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 120
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaacaat cctgcatgat 180
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacctt 240
tattaatgaa ttttcctgct gtaataatgg gtagaaggta attactatta ttattgatat 300
ttaagttaaa ccagtaaat gaagtccatg gaataataga aagagaaaaa gcatttttcag 360
gtataggtgt tttgggaaac aatttccccg aaccattata tttctctaca tcagaaagg 420
ataaatcata aaactctttg aagtcattct ttacaggagt ccaaatacca gagaatgttt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atcccaataa cctaactctc 540
cgctcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcacctt gtcactaaga 600
aaataaatgc agggtaaaat ttatatcctt cttgttttat gtttcgggtat aaaacactaa 660
tatcaatttc tgtgggtata ctaaaagctg tttgttggtt caaataatga ttaaatatct 720
cttttctctt ccaattgtct aaatcaattt tattaaagtt catttgatat gcctcctaaa 780
tttttatcta aagtgaattt aggaggctta cttgtctgct ttcttcatta gaatcaatcc 840
ttttttaaaa gtcaatatta ctgtaacata aatatatatt ttaaaaaatat cccactttat 900
ccaattttcg tttgttgaac taatgggtgc tttagttgaa gaataaagac cacattaaaa 960
aatgtgggtct tttgtgtttt tttaaaggat ttgagcgtag cgaaaaatcc ttttctttct 1020
tatcttgata ataagggtaa ctattgaatt cggtagcaag agtttgtaga aacgcaaaaa 1080
ggccatccgt caggatggcc ttctgcttaa tttgatgcct ggcagtttat ggcgggcgtc 1140
ctgcccgcga cctccggggc cgttgcttcg caacgttcaa atccgctccc ggcgggatttg 1200
tctactcag gagagcgttc accgacaaac aacagataaa acgaaaggcc cagtctttcg 1260
actgagcctt tcgtttttatt tgatgcctgg cagttcccta ctctcgcatg gggagacccc 1320
aactacat cggcgctacg gcgtttcact tctgagttcg gcatggggtc aggtgggacc 1380
accgcgctac tgccgccagg caaattctgt tttatcagac cgcttctgcg ttctgattta 1440

```

atctgtatca	ggctgaaaat	cttctctcat	ccgccaaaac	aggatcccc	atcaacaatt	1500
acacacttct	attgattcta	caaaaaaaga	cattgagttt	caagaacatc	gtcaaaaaac	1560
ccgccgggca	taagcccaag	cgggttttag	gatcttaata	atctaattct	ttataataag	1620
gaaatttata	agtacagagca	gctacacgct	gtcttgcttc	ttcaagtttt	ccttcattctt	1680
cgtgggtttt	caatgcaagc	gcaatgatag	caccgacttc	ttctaatacg	tctccgtcaa	1740
aaccgcggct	ggttacagca	gctgtacca	gacggatgcc	gcttgttacg	aaaggttttt	1800
caggatcata	tggaaatcg	tttttgtag	acgtaatacc	aatttcattca	agtacatgct	1860
ccgcaacctt	accagtcagt	ccgagcgaac	gaaggtaaac	aaggataagg	tgggtgtctg	1920
ttccgcctga	aacgagctgg	atgccctctt	tcgttaaggc	ttcagccaga	cgtttcgcgt	1980
ttgaaatgac	gtttttgtca	tatgttttga	aatcgctctg	caataactca	ccgaatgaaa	2040
cagctttttg	ggcaataacg	tgcatcagag	ggccgccttg	aattccaggg	aagatcgatt	2100
tatcaatttt	cttgccaaac	tcttcacggc	aaaggatcat	accgccgcga	ggaccgcga	2160
gtgtttttat	tgttggtgtt	gtaacgaaat	cagcgtaagg	aaccgggttt	ggatgaaggc	2220
ctgccgcaac	aagtcctg	atatgtgcca	tatccaccat	gaagtaagcg	ccgacttcat	2280
cagcaatttc	acggaatttc	ttaaagtcga	ttgtacgagg	atacgcaact	gctcctgcta	2340
cgataagctt	cggttttatga	gcgagggctt	tttcacgcac	gtcatcgtaa	tcaatatatt	2400
gagtttcttt	atctacgccg	tactcaacaa	agttatatgt	aacaccgctg	aagttgactg	2460
ggcttccgtg	tgttaaattg	ccgccgtggg	agaggttcat	cccaagtaca	gtatcgctt	2520
gctccaaaat	cgtgaagtac	actgccatgt	ttgcttgctg	gcctgaatga	ggctgaacgt	2580
ttacatgctc	cgctccaaag	atttccttcg	cgcggtcacg	ggcgatatct	tcaacgacat	2640
cgacgtgctc	gcatccgccg	tagtagcggt	tgcccgata	tccttctg	tacttatttg	2700
tcaaaacaga	tccttgctg	tccataaccg	cttcacttac	aaagttctca	gaagcaatca	2760
attcgatctt	agtctgttg	cgttcacgct	catttttaaat	ggcgttaaac	acttgttcgt	2820
cttgccgagg	ttaaagtgtt	atgtttacac	ctcctctaga	gcgtcctgct	gttgtaaaga	2880
ttattatacc	acaccttgta	gataaagtca	acaacttttt	gcaaaatttt	tcaggaaattt	2940
tagcagaggt	tgttctggat	gtagaacaaa	acatctttcc	gctcttgctg	tgtaggata	3000
tctttcttgg	aagctaggt	ggcctcgagt	tatggcagtt	ggtaaaaagg	aaacaaaaag	3060
accgttttca	cacaaaacgg	tcttttttga	tttcttttta	cagtcacagc	cactttttga	3120
aaaaccggac	agcttcatgc	cttataactg	ctgtttcggt	cgacaagctt	cgcaagcg	3180
ccgcaaaatt	cactggccgt	cgttttacaa	cgctgtgact	gggaaaacc	tggcgttacc	3240
caacttaatc	gccttgacgc	acatccccct	ttcgccagct	ggcgtaatag	cgaagaggcc	3300
cgcaccgatc	gcccttccca	acagttgcgc	agcctgaatg	gcgaatggcg	cctgatgcgg	3360
tattttctcc	ttacgcatct	gtgcggtatt	tcacaccgca	tatggtgcac	tctcagtaca	3420
atctgctctg	atgccgcata	gttaagccag	ccccgacacc	cgccaacacc	cgctgactat	3480
gcttgtaaac	cgttttgtag	aaaaattttt	aaaataaaaa	aggggacctc	taggggtccc	3540
aattaattag	taatataatc	tattaaaggt	cattcaaaaag	gtcatccacc	ggatcagctt	3600
agtaaagccc	tcgctagatt	ttaatgcgga	tggtgcgatt	acttcgcca	ctattgcgat	3660
aacaagaaaa	agccagcctt	tcatgatata	tctcccaatt	tgtgtagggc	ttattatgca	3720
cgcttaaaaa	taataaaaagc	agacttgacc	tgatagtttg	gctgtgagca	attatgtgct	3780
tagtgcattc	aacgcttgag	ttaagccgcg	ccgcgaagcg	gcgtcggctt	gaacgaattg	3840
ttagacatta	tttgccgact	accttggtga	tctcgctttt	cacgtagtgg	acaaattctt	3900
ccaactgatc	tgccgcgcgag	gccaaagcat	cttcttcttg	tccaagataa	gctgtctag	3960
cttcaagtat	gacgggctga	tactgggccc	gcaggcgctc	cattgccag	tcggcagcga	4020
catccttcgg	cgcgattttg	ccggttactg	cgctgtacca	aatgcgggac	aacgtaagca	4080
ctacatttcg	ctcatcgcca	gcccagtcgg	gcggcgagtt	ccatagcggt	aaggtttcat	4140
ttagcgcctc	aaatagatcc	tggtcaggaa	ccggatcaaa	gagttcctcc	gccgctggag	4200
ctaccaaggc	aacgctatgt	tctcttgctt	ttgtcagcaa	gatagccaga	tcaatgtcga	4260
tcgtggctgg	ctcgaagata	cctgcaagaa	tgatcattgcg	ctgccattct	ccaaattgca	4320
gttcgcgctt	agctggataa	cgccacggaa	tgatgtcgtc	gtgcacaaca	atggtgactt	4380
ctacagcgcg	gagaatctcg	ctctctccag	gggaagccga	agtttccaaa	aggtcgttga	4440
tcaaagctcg	ccgcgttggt	tcatcaagcc	ttacggtcac	cgtaaccagc	aaatcaatat	4500
cactgtgtgg	cttcaggccg	ccatccactg	cggagccgta	caaagtgtacg	gccagcaacg	4560
tcggttcgag	atggcgctcg	atgacgcca	ctacctctga	tagttgagtc	gatacttcgg	4620
cgatcaccgc	ttccctcatg	atgtttaact	ttgttttagg	gcgactgccc	tgctgcgtaa	4680
catcggtgct	gctccataac	atcaaacatc	gacccacggc	gtaacgcgct	tgctgcttgg	4740
atgcccaggg	catagactgt	accccaaaaa	aacagtcata	acaagccatg	aaaaccgcca	4800
ctgcgcggtt	accaccgctg	cgttcgggtc	aggttctgga	ccagttgcgt	gagcgcatat	4860
gctacttgca	ttacagctta	cgaaccgaac	aggcttatgt	ccactgggtt	cgtgccttca	4920
tccgtttcca	cgggtgtgct	caccgggcaa	ccttgggcag	cagcgaagtc	gaggcatttc	4980

```

tgtcctggct ggcgaacgag cgcaagggtt cggtctccac gcatcgtcag gcattggcgg 5040
ccttgctgtt cttctacggc aaggtgctgt gcacggatct gccctggctt caggagatcg 5100
gaagacctcg gccgtcgcg cgcttgccgg tgggtgctgac ccgggatgaa gtgggttcgca 5160
tcctcggtt tctggaaggc gagcatcggt tgttcgccca gcttctgtat ggaacgggca 5220
tgcggtacag tgagggtttg caactgcggg tcaaggatct ggatttcgat cacggcacga 5280
tcacgtgcg ggagggcaag ggctccaagg atcgggcctt gatgttacct gagagcttgg 5340
caccagcct gcgcgagcag gggaattgat ccgggtgatg accttttgaa tgacctttaa 5400
tagattatat tactaattaa ttggggaccc tagagggtccc cttttttatt ttaaaaattt 5460
tttcacaaaa cggtttacaa gcataacggg ttttgctgcc cgcaaacggg ctgttctggt 5520
gttgctagtt tgttatcaga atcgcatcgc cggcttcagg tttgccggct gaaagcgcta 5580
tttcttcag aattgccatg attttttccc cacgggaggc gtcactggct ccggtgttgt 5640
cggcagcttt gattcgataa gcagcatcgc ctgtttcagg ctgtctatgt gtgactgttg 5700
agctgtaaca agttgtctca ggtgttcaat ttcattgtct agttgctttg ttttactggt 5760
ttcacctgtt ctattaggtg ttacatgctg ttcattctgt acattgtcga tctgttcatt 5820
gtgaacagct ttaaatgcac caaaaactcg taaaagctct gatgtatcta tcttttttac 5880
accgttttca tctgtgcata tggacagttt tccctttgat atctaacggg gaacagttgt 5940
tctacttttg tttgttagtc ttgatgcttc actgatagat acaagagcca taagaacctc 6000
agatccttcc gtatttagcc agtatgttct ctagtgtggt tcgttgtttt tgcgtgagcc 6060
atgagaacga accattgaga tcatgcttac tttgcatgtc actcaaaaat tttgcctcaa 6120
aactggtgag ctgaattttt gcagttaaag catcgtgtag tgtttttctt agtccgttac 6180
gtaggtagga atctgatgta atggttgttg gtattttgtc accattcatt tttatctggt 6240
tgttctcaag ttcggttacg agatccattt gtctatctag ttcaacttgg aaaatcaacg 6300
tatcagtcgg gcggcctcgc ttatcaacca ccaatttcat attgctgtaa gtgtttaaat 6360
ctttacttat tggtttcaaa acccattggt taagcctttt aaactcatgg tagttatttt 6420
caagcattaa catgaactta aattcatcaa ggctaattct tatatttgcc ttgtgagttt 6480
tcttttgtgt tagttctttt aataaccact cataaatcct catagagtat ttgttttcaa 6540
aagacttaac atgttccaga ttataatttt tgaatttttt taactggaaa agataaggca 6600
atatctcttc actaaaaact aattctaatt tttcgcttga gaacttggca tagtttgtcc 6660
actggaaaa ctcaaaagct ttaaccaaa gattcctgat ttccacagtt ctogtcatca 6720
gctctctggt tgcttttagct aatacaccat aagcattttt cctactgatg ttcattcatc 6780
gagcgtattg gttataaagt aacgataacc tccgttcttt ccttgtaggg ttttcaatcg 6840
tggggttgag tagtgccaca cagcataaaa ttagcttggt ttcattgctcc gttaagtcatt 6900
agcgactaat cgctagttca tttgctttga aaacaactaa ttcagacata catctcaatt 6960
ggtctaggtg attttaatca ctataccaat tgagatgggc tagtcaatga taattactag 7020
tccttttctt ttgagttgtg ggtatctgta aattctgcta gacctttgct ggaaaacttg 7080
taaattctgc tagaccctct gttaaattccg ctagaccttt gtgtgttttt tttgtttata 7140
ttcaagtggg tataatttat agaataaaga aagaataaaa aaagataaaa agaataagatc 7200
ccagccctgt gtataactca ctactttagt cagttccgca gtattacaaa aggatgtcgc 7260
aaacgtgtt tgctcctcta caaacagac cttaaaacc taaaggctta agtagcacc 7320
tcgcaagctc gggcaaatcg ctgaatattc cttttgtctc cgaccatcag gcacctgagt 7380
cgctgtcttt ttcgtgacat tcagttcgct gcgctcacgg ctctggcagt gaatgggggt 7440
aatggcact acaggcgctt tttatggatt catgcaagga aactacccat aatacaagaa 7500
aagcccgta cgggcttctc agggcggttt atggcggtgc tgctatgtgg tgctatctga 7560
ctttttgctg ttcagcagtt cctgccctct gattttccag tctgaccact tcggattatc 7620
ccgtgacagg tcattcagac tggctaattgc acccagtaag gcagcggtat catcaacagg 7680
cttaccgctc ttactgtcaa c

```

<210> 26

<211> 3888

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid

<400> 26

```

tgccgcgcta cagggcgct ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcgggtcggg cctcttcgct attacgccag tttgggggtg agttcatgaa gtttcgtcgc 120
agcggcagat tgggtggactt aacaaattat ttgttaacc atccgcacga gttaataccg 180

```

ctaaccctttt	tctctgagcg	gtatgaatct	gcaaaatcat	cgatcagtga	agatttaaca	240
attattaaac	aaacctttga	acagcagggg	attgggtactt	tgcttactgt	tcccggagct	300
gccggaggcg	ttaaatatat	tccgaaaatg	aagcaggctg	aagctgaaga	gtttgtgcag	360
acacttgagc	agtcgctggc	aaatcctgag	cgtatccttc	cgggcggtta	tgtatattta	420
acggatatct	taggaaagcc	atctgtactc	tccaaggtag	ggaagctgtt	tgcttccgtg	480
tttgcgagc	gcgaaattga	tggtgtcatg	accgttgcca	cgaagggcat	ccctcttgcg	540
tacgcagctg	caagctatct	gaatgtgcct	gttgtgatcg	ttcgtaaaga	caataaggta	600
acagagggct	ccacagtcag	cattaattac	gtttcaggct	cctcaaaccg	cattcaaaca	660
atgtcacttg	cgaaaagaag	catgaaaacg	ggttcaaacg	tactcattat	tgatgacttt	720
atgaaagcag	gcggcaccat	taatggtagt	attaacctgt	tggaatgagt	taacgcaaat	780
gtggcgggaa	tcggcgctct	agttgaagcc	gaaggagtag	atgaacgtct	tggtgacgaa	840
tatatgtcac	ttcttactct	ttcaaccatc	aacatgaaag	agaagtccat	tgaaattcag	900
aatggcaatt	ttctgcgttt	ttttaaagac	aatcttttaa	agaatggaga	gacagaatca	960
tgacaaaagc	agtccacaca	aaacatgccc	cagcggcaat	cgggccttat	tcacaaggga	1020
ttatcgtaaa	caatatgttt	tacagctcag	gccaaatccc	tttgactcct	tcaggcgaaa	1080
tggtgaatgg	cgatattaag	gagcagactc	atcaagtatt	cagcaattta	aaggcggttc	1140
tggaagaagc	gggtgcttct	tttgaaacag	ttgtaaaagc	aactgtatct	atcgcgata	1200
tggaacagtt	tgcggaagta	aacgaagtgt	acggacaata	ttttgacact	cacaaaccgg	1260
cgagatcttg	tggtgaagtc	gcgagactcc	cgaaggatgc	gttagtcgag	atcgaagtta	1320
ttgactgggt	gaaataataa	gaaaagtgat	tctgggagag	ccgggatcac	ttttttatct	1380
accttatgcc	cgaaatgaaa	gctttatgac	cctgcattaa	tgaatcggcc	aacgcgcggg	1440
gagaggcggt	ttgcgtattg	ggcgctcttc	cgcttccctc	ctcactgact	cgctgcgctc	1500
ggtcgttcgg	ctgcggcgag	cggtatcagc	tcactcaaa	gcggttaata	ggttatccac	1560
agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	1620
ccgtaaaaag	gccgcgttgc	tggcgttttt	cgataggctc	cgccccctg	acgagcatca	1680
caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataaccaggc	1740
gtttccccct	ggaagctccc	tcgtgcgctc	tctgttccg	accctgcgc	ttaccggata	1800
cctgtccgct	tttctccctt	cggaagcgct	ggcgctttct	catagctcac	gctgtaggta	1860
tctcagttcg	gtgtaggctg	ttcgctccaa	gctgggctgt	gtgcacgaac	ccccggttca	1920
gccgaccgcg	tgcgcttat	ccggtactaa	tcgtcttgag	tccaacccgg	taagacacga	1980
cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	2040
tgctacagag	ttcttgaagt	ggtaggcctaa	ctacggctac	actagaagga	cagtatttgg	2100
tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	2160
caaacaacc	accgctggta	gcggtggttt	ttttgtttgc	aagcagcaga	ttacgcgcag	2220
aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	2280
cgaaaactca	cgtaagggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	2340
ccttttaaat	taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	2400
tgacagtta	caatgcttaa	tcagtgaggc	acctatctca	gcgatctgtc	tatttcgttc	2460
atccatagtt	gctgactcc	ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	2520
tgccccagct	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	atttatcagc	2580
aataaaccag	ccagccggaa	gggcccagcg	cagaagtgg	cctgcaactt	tatccgcctc	2640
catccagctc	attaattgtt	gccgggaagc	tagagtaagt	agttcgccag	ttaatagttt	2700
gcgcaacgtt	gttggcattg	ctacaggcat	cgtggtgtca	cgctcgtcgt	ttggtatggc	2760
ttcattcagc	tccggttccc	aacgatcaag	gcgagttaca	tgatcccca	tggtgtgcaa	2820
aaaagcgggt	agctccttcg	gtcctccgat	cgttgtcaga	agtaagttgg	ccgcagtgtt	2880
atcactcatg	gttatggcag	cactgcataa	ttctcttact	gtcatgccat	ccgtaagatg	2940
cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	gaataccgcg	cccggcgacc	3000
gagttgctct	tgcccgcgct	caatacggga	taatagtgt	tgacatagca	gaactttaaa	3060
agtgtcatc	attggaaaac	gttcttcggg	gcgaaaactc	tcaaggatct	taccgctgtt	3120
gagatccagt	tcgatgtaac	ccactcgtgc	acccaactga	tcttcagcat	cttttacttt	3180
caccagcgtt	tctgggtgag	caaaaacagg	aaggcaaaat	gccgcaaaaa	agggaataag	3240
ggcgacacgg	aatgttgaa	tactcatact	cttccctttt	caatattatt	gaagcattta	3300
tcagggttat	tgtctcatga	gcggatacat	atttgaatgt	atttagaaaa	ataaacaat	3360
aggggttccg	cgcacatttc	cccgaaaagt	gccacctgta	tgcggtgtga	aataccgcac	3420
agatgcgtaa	ggagaaaata	ccgcacagc	cgaaattgta	aacgttaata	ttttgttaaa	3480
attcgcgtta	aatatttgtt	aatcagctc	attttttaac	caataggccg	aaatcggcaa	3540
aatcccttat	aaatcaaaag	aatagaccga	gatagggttg	agtgttggtc	cagtttggaa	3600
caagagtcca	ctattaaaga	acgtggactc	caacgtcaaa	gggcgaaaaa	ccgtctatca	3660
ggcgatggc	ccactacgtg	aacctacc	caaatcaagt	tttttgcggt	cgagggtgccg	3720


```

taaagctcta aatcggaacc ctaaagggag ccccgattt agagcttgac ggggaaagcc 3780
ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga gcgggcgcta gggcgctggc 3840
aagtgtagcg gtcacgctgc gcgtaaccac cacaccgcgc gcgcttaa 3888

```

<210> 27

<211> 4606

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 27

```

tgcgcgcgcta cagggcgcgct ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagttggg taacgccagg gttttccag tcacgacgtt gtaaacgac ggccagtga 180
ttgtaatacg actcactata gggcgaattg ggcccgacgt cgcattgctcc cggccgccat 240
ggccgcggga tgcggccgcg tcgacgtgaa ataccgcaca gatgcgtaag gagaaaatac 300
cgcatcaggc gataaaccca gcgaaccatt tgaggtgata ggtaagatta taccgaggta 360
tgaaaacgag aattggacct ttacagaatt actctatgaa gcgccatatt taaaaagcta 420
ccaagacgaa gaggatgaag aggatgagga ggcagattgc cttgaatata ttgacaatac 480
tgataagata atatatcttt tatatagaag atatcgccgt atgtaaggat ttcagggggc 540
aaggcatagg cagcgcgctt atcaatatat ctatagaatg ggcaaagcat aaaaacttgc 600
atggactaat gcttgaaacc caggacaata accttatagc ttgtaaattc tatcataatt 660
gtggtttcaa aatcggtccc gtcgatacta tgttatacgc caactttcaa aacaactttg 720
aaaaagctgt tttctggtat ttaaggtttt agaatgcaag gaacagtga ttggagtctg 780
tcttgttata attagcttct tggggtatct ttaaatactg tagaaaagag gaaggaaata 840
ataaatggct aaaatgagaa tatcaccgga attgaaaaaa ctgacgaaa aataccgctg 900
cgtaaaagat acggaaggaa tgtctcctgc taaggatat aagctggttg gagaaaatga 960
aaacctatat ttaaaaatga cggacagccg gtataaaggg accacctatg atgtggaacg 1020
ggaaaaggac atgatgctat ggctggaagg aaagctgcct gttccaaagg tcctgcactt 1080
tgaacggcat gatggctgga gcaatctgct catgagtga gccgatggcg tcctttgctc 1140
ggaagagtat gaagatgaac aaagccctga aaagattatc gagctgtatg cggagtgcac 1200
caggctcttt cactccatcg acatatcgga ttgtccctat acgaatagct tagacagccg 1260
cttagccgaa ttggattact tactgaataa cgatctggcc gatgtggatt gcgaaaactg 1320
ggaagaagac actccattta aagatccgcg cgagctgtat gattttttta agacggaaaa 1380
gcccgaagag gaacttgtct tttccacagg cgacctggga gacagcaaca tctttgtgaa 1440
agatggcaaa gtaagtggct ttattgatct tgggagaagc ggcagggcgg acaagtggta 1500
tgacattgcc tctcgctcc ggtcgatcag ggaggatatc ggggaagaac agtatgtcga 1560
gctatTTTTT gacttactgg ggatcaagcc tgattgggag aaaataaaat attatatTTT 1620
actggatgaa ttgttttagt acctagattt agatgtctaa aaagctttta ctacaagctt 1680
tttagacatc taatcttttc tgaagtacat ccgcaactgt ccatactctg atgttttata 1740
tcttttctaa aagttcgcta gataggggtc ccgagcgctc acgaggaatt tgtatcgcca 1800
ttcgccatc aggctgcgca actgttggga agggcgatcg gtgcgggtac cgggatcact 1860
agtgcggccg cctgcaggtc gaccatatgg gagagctccc aacgcgttgg atgcatagct 1920
tgagtattct atagtgtcac ctaaatagct tggcgtaatc atggtcatag ctgtttcctg 1980
tgtgaaattg ttatccgctc acaattccac acaacatacg agccggaagc ataaagtgta 2040
aagcctgggg tgctaataga gtgagctaac tcacattaat tgcgttgcg cactgcccg 2100
ctttccagtc gggaaacctg tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga 2160
gaggcggttt gcgtattggg cgctcttccg cttcctcgct cactgactcg ctgcgctcgg 2220
tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag 2280
aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc 2340
gtaaaaaggc gcggttgctg gcgtttttcg ataggtccg cccccctgac gagcatcaca 2400
aaaatcgacg ctcaagtacg aggtggcgaa acccgacagg actataaaga taccaggcgt 2460
ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc 2520
tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc tgtaggtatc 2580
tcagttcggg gtaggtcggt cgctccaagc tgggctgtgt gcacgaacc cccgttcagc 2640
ccgaccgctg cgcttatcc ggtaactatc gtcttgagtc caaccggtg agacacgact 2700
tatcgccact ggcagcagcc actggttaaca ggattagcag agcgaggtat gtaggcggtg 2760

```

```

ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggtgta 2820
tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca 2880
aacaaccac cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa 2940
aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaaacg 3000
aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc 3060
ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttgggtctg 3120
acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat 3180
ccatagttgc ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg 3240
gccccagtgc tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa 3300
taaacagcac agccggaagg gccgagcgca gaagtggccc tgcaacttta tccgcctcca 3360
tccagtcctat taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc 3420
gcaacgttgt tggcattgct acaggcatcg ttggttcacg ctgctcgttt ggtatggctt 3480
cattcagctc cggttcccaa cgatcaaggc gatttacatg atccccatg ttgtgcaaaa 3540
aagcggtag ctcttccggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat 3600
cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct 3660
tttctgtgac tggtagtagc tcaaccaagt cattctgaga ataccgcgcc cggcgaccga 3720
gttgcctctg cccggcgtca atacgggata atagtgtatg acatagcaga actttaaaag 3780
tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga 3840
gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca 3900
ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg 3960
cgacacggaa atgttgaata ctcatactct tcttttttca atattattga agcatttatc 4020
agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag 4080
gggttccgcg cacatttccc cgaaaagtgc cactgtatg cgggtgtgaaa taccgcacag 4140
atgcgtaagg agaaaatacc gcatacaggc aaattgtaaa cgtaaatatt ttgttaaaat 4200
tcgcgttaaa tatttggttaa atcagctcat tttttaacca ataggccgaa atcggcaaaa 4260
tcccttataa atcaaaagaa tagaccgaga taggggttag tgttgttcca gtttggaaca 4320
agagtcact attaaagaac gtggactcca acgtcaaagg gcgaaaaacc gtctatcagg 4380
gcgatggccc actacgtgaa ccatcaccca aatcaagttt tttgcggtcg aggtgccgta 4440
aagctctaaa tcggaaccct aaaggagacc cccgatttag agcttgacgg ggaagccgg 4500
cgacgtggc gagaaaggaa gggaagaaag cgaaaggagc gggcgctagg gcgctggcaa 4560
gtgtagcggc cacgctgcgc gtaaccacca caccgcgcgc gcttaa 4606

```

<210> 28

<211> 5399

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 28

```

tgcgcgcgta cagggcgcgt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcggtgcggg cctcttcgct attacgccag tttgggggtg agttcatgaa gtttcgtcgc 120
agcggcagat tggtagactt aacaaattat ttgttaacc atccgcacga gtaataaccg 180
ctaacccttt tctctgagcg gtatgaatct gcaaaatcat cgatcagtga agatttaaca 240
attattaaac aaacctttga acagcagggg attggtactt tgcttactgt tcccgagct 300
gccggaggcg ttaaataat tccgaaaatg aagcaggctg aagctgaaga gtttgtgcag 360
acacttgagc agtcgctggc aaatcctgag cgtatccttc cgggcggtta tgtatattta 420
acggatatct taggaaagcc atctgtactc tcaaggtag ggaagctgtt tgcttccgtg 480
tttgacagagc gcgaaattga tgttgtcatg accgttgcca cgaaaggcat ccctcttcgc 540
tacgcagctg cggccgcgct gacaaacca gtgaaccatt tgaggtgata ggtaagatta 600
taccgaggtg tgaaaacgag aattggacct ttacagaatt actctatgaa gcgccatatt 660
taaaaagcta ccaagacgaa gaggatgaag aggatgagga ggcagattgc cttgaatata 720
ttgacaatac tgataagata atatatcttt tatatagaag atatcgccgt atgtaaggat 780
ttcagggggc aaggcatagg cagcgcgctt atcaatatat ctatagaatg ggcaaagcat 840
aaaaacttgc atggactaat gcttgaaacc caggacaata accttatagc ttgtaaatc 900
tatcataatt gtggtttcaa aatcggctcc gtcgatacta tgttatacgc caactttcaa 960
aacaactttg aaaaagctgt tttctggtat ttaaggtttt agaattgcaag gaacagtga 1020
ttggagttcg tcttgttata attagcttct tggggtatct ttaaatactg tagaaaagag 1080

```

gaaggaaata	ataaatggct	aaaatgagaa	tatcaccgga	attgaaaaaa	ctgatcgaaa	1140
aataccgctg	cgtaaaagat	acggaaggaa	tgtctcctgc	taagggtatat	aagctggtgg	1200
gagaaaatga	aaacctatat	ttaaaaatga	cggacagccg	gtataaaggg	accacctatg	1260
atgtggaacg	ggaaaaggac	atgatgctat	ggctggaagg	aaagctgcct	gttccaaagg	1320
tcctgcactt	tgaacggcat	gatggctgga	gcaatctgct	catgagttag	gccgatggcg	1380
tcctttgctc	ggaagagtat	gaagatgaac	aaagccctga	aaagattatc	gagctgtatg	1440
cggagtgcac	caggctcttt	cactccatcg	acatatcgga	ttgtccctat	acgaatagct	1500
tagacagccg	cttagccgaa	ttggattact	tactgaataa	cgatctggcc	gatgtggatt	1560
gcgaaaactg	ggaagaagac	actccattta	aagatccgcg	cgagctgtat	gattttttaa	1620
agacggaaaa	gcccgaagag	gaacttgtct	tttcccacgg	cgacctggga	gacagcaaca	1680
tcctttgtgaa	agatggcaaaa	gtaagtggct	ttattgatct	tgggagaagc	ggcaggcgcg	1740
acaagtggta	tgacattgcc	ttctgcgtcc	ggctgatcag	ggaggatatac	ggggaagaac	1800
agtatgtcga	gctatttttt	gacttactgg	ggatcaagcc	tgattgggag	aaaataaaat	1860
attatatatt	actggatgaa	ttgttttagt	acctagattt	agatgtctaa	aaagctttta	1920
ctacaagctt	tttagacatc	taatcttttc	tgaagtacat	ccgcaactgt	ccatactctg	1980
atgttttata	tcctttctaa	aagtctgcta	gataggggtc	ccgagcgccct	acgaggaatt	2040
tgtatcacca	ggtaccagct	gcaagctatt	tgaatgtgcc	tggtgtgatc	gttcgtaaaag	2100
acaataaggt	aacagagggc	tccacagtca	gcattaatta	cgtttcaggc	tcctcaaacc	2160
gcattcaaac	aatgtcactt	gcgaaaagaa	gcatgaaaac	gggttcaaac	gtactcatta	2220
ttgatgactt	tatgaaagca	ggcggcacca	ttaatggtat	gattaacctg	ttggatgagt	2280
ttaacgcaaa	tgtggcgggg	atcggcgctc	tagttgaagc	cgaaggagta	gatgaacgtc	2340
ttgttgacga	atatatgtca	cttcttactc	tttcaaccat	caacatgaaa	gagaagtcca	2400
ttgaaattca	gaatggcaat	tttctgcgtt	tttttaaaga	caatctttta	aagaatggag	2460
agacagaatc	atgacaaaag	cagtcacac	aaaacatgcc	ccagcggcaa	tcgggcctta	2520
ttcacaaggg	attatcgta	acaatatggt	ttacagctca	ggccaaatcc	ctttgactcc	2580
ttcaggcgaa	atggtgaatg	gcgatattaa	ggagcagact	catcaagtat	tcagcaattt	2640
aaaggcggtt	ctggaagaag	cgggtgcttc	ttttgaaaca	gttgtaaaag	caactgtatt	2700
tatcgcggat	atggaacagt	ttgcggaagt	aaacgaagtg	tacggacaat	attttgacac	2760
tcacaaaccg	gcgagatcct	gtgttgaaat	cgcgagactc	ccgaaggatg	cgttagtcca	2820
gatcgaaagt	attgcactgg	tgaaataata	agaaaaagtga	ttctgggaga	gccgggatca	2880
cttttttatt	taccttatgc	ccgaaatgaa	agctttatga	ccctgcatta	atgaatcggc	2940
caacgcgcgg	ggagaggcgg	tttgcgtatt	gggcgctctt	ccgcttcctc	gctcactgac	3000
tcgctgcgct	cggtcggtcg	gctgcggcga	gcggtatcag	ctcactcaaa	ggcggtaata	3060
cggttatcca	cagaatcagg	ggataacgca	ggaaagaaca	tgtgagcaaa	aggccagcaa	3120
aaggccagga	accgtaaaaa	ggccgcgttg	ctggcggttt	tcgataggct	ccgccccctt	3180
gacgagcatc	acaaaaaatcg	acgctcaagt	cagaggtggc	gaaacccgac	aggactataa	3240
agataccagg	cgtttccccc	tggaagctcc	ctcgtgcgct	ctcctgttcc	gacctgccc	3300
cttaccggat	acctgtccgc	ctttctccct	tcgggaagcg	tggcgctttc	tcatagtcca	3360
cgctgtaggt	atctcagttc	ggtgtaggtc	gttcgctcca	agctgggctg	tgtgcacgaa	3420
cccccggttc	agcccagaccg	ctgcgcctta	tccggtaaat	atcgtcttga	gtccaacccg	3480
gtaagacacg	acttatcgcc	actggcagca	gccactggta	acaggattag	cagagcgagg	3540
tatgtaggcg	gtgctacaga	gttcttgaag	tggtggccta	actacggcta	cactagaagg	3600
acagtatttg	gtatctgcgc	tctgctgaag	ccagttacct	tcggaaaaag	agttggtagc	3660
tcttgatccg	gcaaacaaac	caccgctggt	agcgttggtt	tttttggttg	caagcagcag	3720
attacgcgca	gaaaaaaagg	atctcaagaa	gatcctttga	tcttttctac	ggggtctgac	3780
gctcagtgga	acgaaaaactc	acgttaaggg	attttgggtca	tgagattatc	aaaaaggatc	3840
ttcacctaga	tcctttttaa	ttaaaaaatga	agttttaaat	caatctaaag	tatatatgag	3900
taaaacttgg	ctgacagtta	ccaatgctta	atcagtgagg	cacctatctc	agcgatctgt	3960
ctatttcggt	catccatagt	tgctgactc	cccgtcggtg	agataactac	gatacgggag	4020
ggcttaccat	ctggccccag	tgctgcaatg	ataccgcgag	acccacgctc	accggctcca	4080
gatttatcag	caataaacca	gccagccgga	agggccgagc	gcagaagtgg	tcctgcaact	4140
ttatccgcct	ccatccagtc	tattaattgt	tgccgggaag	ctagagtaag	tagttcgcca	4200
gttaatagtt	tgcgcaacgt	tggtggcatt	gctacaggca	tcgtggtgtc	acgctcgctg	4260
tttggtatgg	cttcattcag	ctccggttcc	caacgatcaa	ggcgagttac	atgatcccc	4320
atgttgtgca	aaaaagcggg	tagctccttc	ggtcctccga	tcgttgtcag	aagtaagttg	4380
gccgcagtgt	tatcactcat	ggttatggca	gcactgcata	attctcttac	tgtcatgcca	4440
tccgtaagat	gcttttctgt	gactggtag	tactcaacca	agtcattctg	agaataccgc	4500
gcccgcgac	cgagttgctc	ttgcccgcg	tcaatacggg	ataatagtgt	atgacatagc	4560
agaactttta	aagtgtcat	cattggaaaa	cgttcttcgg	ggcgaaaact	ctcaaggatc	4620

```

ttaccgctgt tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca 4680
tcttttactt tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa 4740
aagggaataa gggcgacacg gaaatgttga atactcatac tcttcctttt tcaatattat 4800
tgaagcattt atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa 4860
aataaaciaa taggggttcc gcgcacattt ccccgaaaag tgccacctgt atgcggtgtg 4920
aaataccgca cagatgcgta aggagaaaat accgcacag gcgaaattgt aaacgttaat 4980
atthttgtta aattcgcgtt aaatatttgt taaatcagct cattttttta ccaataggcc 5040
gaaatcgga aaatccctta taaatcaaaa gaatagaccg agatagggtt gagtgttgtt 5100
ccagtttga acaagagtcc actattaaag aacgtggact ccaacgtcaa agggcgaaaa 5160
accgtctatc agggcgatgg cccactacgt gaaccatcac ccaaatcaag ttttttgcgg 5220
tcgagggtgc gtaaagctct aaatcggaac cctaaaggga gccccgatt tagagcttga 5280
cggggaaaag cggcgaaagt ggcgagaaag gaagggaaga aagcgaaaag agcgggcgct 5340
agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacaccgc cgcgcttaa 5399

```

<210> 29

<211> 6805

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 29

```

ttgcggccgc ttcgaaagct gtaatatataa aaccttcttc aactaacggg gcaggttagt 60
gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120
tcattaggcc tatctgacaa ttctgaata gagttcataa acaatcctgc atgataacca 180
tcacaaacag aatgatgtac ctgtaaagat agcggtaaat atattgaatt acctttatta 240
atgaattttc ctgctgtaat aatgggtaga aggttaattac tattattatt gatatttaag 300
ttaaaccag taaatgaagt ccattggaata atagaaagag aaaaagcatt ttcaggata 360
ggtgttttgg gaaacaattt ccccgaaacca ttatatttct ctacatcaga aaggatataa 420
tcataaaact ctttgaagtc attctttaca ggagtccaaa taccagagaa tgttttagat 480
acaccatcaa aaattgtata aagtggctct aacttatccc aataaccta ctctccgtcg 540
ctattgtaac cagttctaaa agctgtattt gagtttatca cccttgtcac taagaaaata 600
aatgcagggt aaaatttata tccttcttgt tttatgtttc ggtataaaac actaatatca 660
atthtctgtg ttatactaaa agtcgtttgt tggttcaaat aatgattaaa tatctctttt 720
ctcttccaat tgtctaaatc aatthtatta aagttcattt gatatgcctc ctaaaatttt 780
atctaaagtg aatthaggag gcttacttgt ctgctttctt cattagaatc aatccttttt 840
taaaagtcaa tattactgta acataaatat atatttttaa aatatccac tttatccaat 900
tttctgttgt tgaactaatg ggtgctttag ttgaagaata aagaccacat taaaaaatgt 960
ggtcttttgt gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct 1020
tgataataag ggtaactatt gaattcggta ccaagagttt gtagaaacgc aaaaaggcca 1080
tcgctcagga tggccttctg cttaatttga tgccctggcag tttatggcgg gcgtcctgcc 1140
cgccaccctc cgggcggttg cttcgcaacg ttcaaaccg ctcccggcgg atttgtcta 1200
ctcaggagag cgttcaccga caaacaacag ataaaacgaa aggccagtc tttcgactga 1260
gcctttcgtt ttatttgatg cctggcagtt ccctactctc gcatggggag accccacact 1320
accatcgcg ctacggcggt tcacttctga gttcggcatg gggtcaggtg ggaccaccgc 1380
gctactgccg ccaggcaaat tctgttttat cagaccgctt ctgcttctg atttaactgt 1440
tatcaggctg aaaatcttct ctcactcgcc aaaacaggat ccaattatgg cagatcaatg 1500
agcttcacag acacaatatc agggacattt gttagtctct tcacaatttt atcttcaga 1560
tgtctgtcaa aggaaagcat catgatggct tctccgctt tttccttacg gccaacctgc 1620
atagttgcaa tgtaatatc attatctcgg agaatacgtc ctactcggcc gatgacacct 1680
gttgatctct gatgctggat atacaccaag tgaccagtcg gataaaaatc aatattaaat 1740
ccattgatct cgacaattcg ttctccgaaa tgaggaaat acgtagccgt tacagtaaag 1800
gtgctgcgg ctctgtcac ttttacgctg atgcagttat cgtatccaga ttcagaagag 1860
gaaatttttt cactgaagct aatgccgct tcttttgcga ccccccggc attgacctca 1920
ttaacagtag agtctacgcg cggtttttaa aagcctgaca gaagggttt tgtaatgaac 1980
gatgtttcaa gtttagcaat tgtgccttca tattgaatgg caacatcctg tactggttct 2040
ttcatgcact gtgatacaag gctgccaatt tttcctgcaa tttgatggta aggccttaatt 2100
ttagcaaat catcttttgt catggcaggc aggttgatag ctgacatgac aggcaggcct 2160

```

tttgcgaact	gcagaacttc	ttctgacact	tgggcggcga	cattgagctg	tgcttctttc	2220
gttgatgctc	ccaagtgagg	agtggcaatg	actaatggat	gatcaacaag	tttggtgtca	2280
actggcgggt	cgacttcgaa	aacgtcaagc	gctgctccc	caacatgcc	gttttccaaa	2340
gcttcgagaa	gtgctgcttc	atcgataatt	ccgcctcgcg	cacagttaat	taagcgaacg	2400
ccttttttcg	tttttgcaat	cgtttcttta	ttcaataagc	cttttgtttc	ttttgttaaa	2460
ggcgtgtgaa	cggtaatgat	atccgcactt	tcaagcactt	cttcaaatgt	acggctgttt	2520
acgccgattt	ttttcgctct	ttcttccgtt	aagaaaggat	caaaaacgtg	cacagtcata	2580
ccgaacgctc	ctcgacgctg	tgcaatttca	cttccgattc	ggcctaatac	tacaatacca	2640
agcgtttttc	cataaagctc	tgaaccgaca	taagctgtgc	ggttccactc	tctggatttc	2700
actgagatat	tagcctgcgg	aatgtgtctc	attaaagaag	agatcattgc	aaatgtatgc	2760
tcagctgtcg	aaatggtgtt	gccgttcgga	gcattgatca	cgattacccc	gtgtttcgta	2820
gcctcatcaa	tatcgatatt	atcgacaccg	acaccggctc	ttccgacaat	ttttaagaa	2880
gtcattttgt	tgaaaaggtc	ttctgttact	tttgtcgcg	ttcgaccaa	aagagcatca	2940
aaagtatgta	attcatcttc	tgcatctgct	acgttttttt	gaacgatttc	aataaagtct	3000
gattcaataa	gtggctgtaa	accgtcggtt	ctcattttgt	ctgagaccaa	tactcgaaac	3060
atgttttctc	ctcctctaga	gcgtcctgct	gttggttaaga	ttattatacc	acaccttgta	3120
gataaagtca	acaacttttt	gcaaaatttt	tcaggaattt	tagcagaggt	tgttctggat	3180
gtagaacaaa	acatctttcc	gctcttgtgc	tgtaggata	tctttcttgg	aagctaggta	3240
ggcctcgagt	tatggcagtt	ggttaaaagg	aaacaaaaag	accgttttca	cacaaaacgg	3300
tctttttcga	tttcttttta	cagtcacagc	cacttttgca	aaaaccggac	agcttcatgc	3360
cttataactg	ctgtttcggt	cgacctgcag	gcatgcaagc	ttcgcgagc	ggccgcccgc	3420
gcgaggctgg	atggccttcc	ccattatgat	tcttctcgct	tccggcggca	tcgggatgcc	3480
cgcgttgag	gccatgctgt	ccaggcaggt	agatgacgac	catcagggac	agcttcaagg	3540
atcgctcgcg	gctcttacca	gcctaacttc	gatcactgga	ccgctgatcg	tcacggcgat	3600
ttatgccgcc	tcggcgagca	catggaacgg	gttggcatgg	attgtaggcg	ccgccctata	3660
ccttgtctgc	ctccccgcgt	tgctgcggg	tgcatggagc	cgggccacct	cgacctgaat	3720
ggaagccggg	ggcacctcgc	taacggattc	accactccaa	gaattggagc	caatcaattc	3780
ttgcggagaa	ctgtgaatgc	gcaaaccaac	ccttggcaga	acatatccat	cgcgtccgcc	3840
atctccagca	gccgcacgcg	gcgcactcgc	ggcagcgttg	ggtcctggcc	acgggtgcgc	3900
atgatcgctg	tccgtgcgtt	gaggaccggg	ctaggctggc	gggggttgcc	tactggttag	3960
cagaatgaat	caccgatacg	cgagcgaacg	tgaagcgact	gctgctgcaa	aacgtctgcg	4020
acctgagcaa	caacatgaat	ggtcttcggg	ttccgtgttt	cgtaaagtct	ggaaacgcgg	4080
aagtcagcgc	cctgcaccat	tatgttccgg	atctgcacgc	caggatgctg	ctggctaccc	4140
tgtggaacac	ctacatctgt	attaacgaag	cgctggcatt	gacctgaggt	gatttttctc	4200
tggtcccggc	gcatccatac	cgccagttgt	ttaccctcac	aacgttccag	taaccgggca	4260
tggtcatcat	cagtaacccg	tatcgtgagc	atcctctctc	gtttcatcgg	tatcattacc	4320
cccatgaaca	gaaattcccc	cttacacgga	ggcatcaagt	gaccaaacag	gaaaaaaccc	4380
cccttaacat	ggccccgctt	atcagaagcc	agacattaac	gcttctggag	aaactcaacg	4440
agctggacgc	ggatgaacag	gcagacatct	gtgaatcgct	tcacgaccac	gctgatgagc	4500
tttaccgcag	ctgcctcgcg	cgtttcgggt	atgacgggtg	aaacctctga	cacatgcagc	4560
tcccggagac	ggtcacagct	tgtctgtaag	cggatgccgg	gagcagacaa	gcccgtcagg	4620
gcgcgtcagc	gggtgttggc	gggtgtcggg	gcgcagccat	gaccagtcga	cgtagcgata	4680
gcggagtgtg	tactggctta	actatgcggc	atcagagcag	attgtactga	gagtgcacca	4740
tatgcggtgt	gaaataccgc	acagatgcgt	aaggagaaaa	taccgcatca	ggcgtcttct	4800
cgcttccctg	ctcactgact	cgctgcgctc	ggtcgttcgg	ctgcggcgag	cggatatcagc	4860
tcactcaaa	gcggtaatac	ggttatccac	agaatcaggg	gataacgcag	gaaagaacat	4920
gtgagcaaaa	ggccagcaaa	aggccaggaa	ccgtaaaaag	gccgcgttgc	tggcggtttt	4980
ccataggctc	cgcccccttg	acgagcatca	caaaaatcga	cgctcaagtc	agaggtggcg	5040
aaacccgaca	ggactataaa	gataccaggc	gtttccccct	ggaagctccc	tcgtgcgctc	5100
tcctgttccg	accctgccgc	ttaccggata	cctgtccgcc	tttctccctt	cgggaagcgt	5160
ggcgctttct	catagctcac	getgtaggta	tctcagttcg	gtgtaggctg	ttcgctccaa	5220
gctgggctgt	gtgcacgaac	cccccgttca	gcccagccgc	tgcgccctat	ccggttaacta	5280
tcgtcttgag	tccaacccgg	taagacacga	cttatcgcca	ctggcagcag	ccactggtaa	5340
caggattagc	agagcgaggt	atgtaggcgg	tgctacagag	ttcttgaagt	ggtggcctaa	5400
ctacggctac	actagaagga	cagtatttgg	tatctgcgct	ctgctgaagc	cagttacctt	5460
cggaaaaaga	gttggttagct	cttgatccgg	caaacaaacc	accgctggta	gcgggtggtt	5520
ttttgtttgc	aagcagcaga	ttacgcgcag	aaaaaaagga	tctcaagaag	atcctttgat	5580
cttttctacg	gggtctgacg	ctcagtgga	cgaaaactca	cgtaaggga	ttttggtcat	5640
gagattatca	aaaaggatct	tcacctagat	ccttttaaat	taaaaatgaa	gttttaaatc	5700

```

aatctaaagt atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtgaggc 5760
acctatctca gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta 5820
gataactacg atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga 5880
cccacgctca ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg 5940
cagaagtggc cctgcaactt tatccgcctc catccagttc attaatgtt gccgggaagc 6000
tagagtaagt agttcgccag ttaatatgtt gcgcaacggt gttgccattg ctgcaggcat 6060
cgtgggtgta cgctcgtcgt ttggtatggc ttcatcagc tccggttccc aacgatcaag 6120
gcgagttaca tgatccccc tggtgtgcaa aaaagcgggt agctccttcg gtcctccgat 6180
cgttgtcaga agtaagttgg ccgcagtggt atcactcatg gttatggcag cactgcataa 6240
ttctcttact gtcatgccat ccgtaagatg cttttctgtg actggtgagt actcaaccaa 6300
gtcattctga gaatagtgtg tgcggcgacc gagttgctct tgcccggcgt caatacggga 6360
taataccgcg ccacatagca gaactttaaa agtgctcatc attggaaaac gttcttcggg 6420
gcgaaaactc tcaaggatct taccgctgtt gagatccagt tcgatgtaac ccactcgtgc 6480
acccaactga tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg 6540
aaggcaaaat gccgcaaaaa agggaataag ggcgacacgg aaatgttgaa tactcatact 6600
cttccttttt caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat 6660
atltgaatgt atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt 6720
gccacctgac gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat 6780
cacgaggccc tttcgtcttc aagaa

```

<210> 30

<211> 5983

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 30

```

tgcgccgcta cagggcgcggt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagtggg taacgccagg gttttccag tcacgacgtt gtaaaacgac ggccagtga 180
ttgtaatacg actcactata gggcgaattg ggcccgacgt cgcattgctc cggccgcat 240
ggccgcggga tatcactagt gcggcgcct gcaggtcgac catatgggag agcccgatc 300
caattatggc agatcaatga gcttcacaga cacaatatca gggacatttg ttagttcttt 360
cacaatttta tcttcagat gtctgtcaaa ggaaagcatc atgatggctt ctccgccttt 420
ttccttacgg ocaacctgca tagttgcaat gttaatatca ttatctccga gaatacgtc 480
tactcggccg atgacacctg ttgtatcttg atgctggata tacaccaagt gaccagtcg 540
ataaaaaatc atattaaatc cattgatctc gacaattcgt tctccgaaat gaggaatata 600
cgtagccgtt acagtaaagg tgcgcggtc tctgtcact tttacgtgta tgcagttatc 660
gtatccagat tcagaagagg aaattttttc actgaagcta atgccgcgtt cttttgcgac 720
accccgcca ttgacctcat taacagtaga gtctacgcgc ggttttaaaa agcctgacag 780
aagggtcttt gtaatgaacg atgtttcaag ttagcaatt gtgccttcat attgaatggc 840
aacatcctgt actggttctt tcatgcactg tgatacaagg ctgccaattt ttcttgaat 900
ttgatggtaa ggcttaattt tagcaaattc atcttttgtc atggcaggca ggttgatag 960
tgacatgaca ggcaggcctt ttggaactg cagaacttct tctgacactt gggcgcgac 1020
attgagctgt gottctttcg ttgatgctcc caagttagga gtggcaatga ctaatggatg 1080
atcaacaagt ttgttgtcaa ctggcggttc gacttcgaaa acgtcaagcg ctgctccgc 1140
aacatgcccg ttttccaaag ctttttagac atctaaatct aggtactaaa acaattcatc 1200
cagtaaaata taatatttta ttttctocca atcaggcttg atcccagta agtcaaaaaa 1260
tagctcgaca tactgttctt ccccgatata ctccctgatc gaccggacgc agaaggcaat 1320
gtcataccac ttgtccgccc tgcgcttct cccaagatca ataaagccac ttactttgcc 1380
atctttcaca aagatgttgc tgtctcccag gtgcgcgtgg gaaaagacaa gttcctcttc 1440
gggcttttcc gtcttttaaaa aatcatacag ctgcgcggga tctttaaatg gagtgtcttc 1500
ttcccagttt tcgcaatcca catcgccag atcgttatc agtaagtaat ccaattcggc 1560
taagcggctg tctaagctat tcgtataggg acaatccgat atgtcgatgg agtgaaagag 1620
cctgatgcac tccgcataca gctcgataat cttttcaggg ctttgttcat cttcatactc 1680
ttccgagcaa aggacgccat cggcctcact catgagcaga ttgctccagc catcatgccg 1740
ttcaaagtgc aggacctttg gaacaggcag ctttccttc agccatagca tcatgtcctt 1800

```

ttcccgttcc	acatcatag	tggtcccttt	ataccggctg	tccgtcattt	ttaaatatag	1860
gttttcattt	tctcccacca	gcttatatac	cttagcagga	gacatttcctt	ccgtatcttt	1920
tacgcagcgg	tatttttcga	tcagtttttt	caattccggg	gatatttctca	ttttagccat	1980
ttattatttc	cttcctcttt	tctacagtat	ttaaagatac	cccaagaagc	taattataac	2040
aagacgaact	ccaattcact	gttccttgca	ttctaaaacc	ttaaatacca	gaaaacagct	2100
ttttcaaagt	tgttttgaaa	gttggcgat	aacatagtat	cgacggagcc	gattttgaaa	2160
ccacaattat	gatagaattt	acaagctata	aggttattgt	cctgggtttc	aagcattagt	2220
ccatgcaagt	ttttatgctt	tgcccattct	atagatatat	tgataagcgc	gctgcctatg	2280
ccttgccccc	tgaaatcctt	acatacggcg	atatcttcta	tataaaagat	atattatctt	2340
atcagatttg	tcaatatatt	caaggcaatc	tgccctctca	tcctcttcat	cctcttcgtc	2400
ttggtagctt	tttaaataatg	gcgcttcata	gagtaattct	gtaaagggtcc	aattctcgtt	2460
ttcatacctc	ggtataatct	tacctatcac	ctcaaattgg	tcgctgggtt	tatcgccctga	2520
tgcggtattt	tctccttacg	catctgtgcg	gtatttcacg	tcgacgcggc	cgccatggcc	2580
gcgggatccc	ggtaccgaaa	catcgtaga	tttcctccta	aattgacaaa	ctaaatatct	2640
gataatttaa	catatttctca	aaagagtgtc	aacgtgtatt	gacgcagtaa	aggataaaaag	2700
taaagcctaa	taaatacaatg	atctgacagc	ttgcaggtaa	tatatattaat	ttgaagcaat	2760
tctctataca	gccaaccagt	tatcgtttat	aatgtaatta	aatttcatat	gatcaatctt	2820
cggggcaggg	tgaaattccc	taccggcggt	gatgagccaa	tggtcttaag	cccgcgagct	2880
gtctttacag	caggattcgg	tgagattccg	gagccgacag	tacagtctgg	atgggagaag	2940
atggaggttc	ataagcgttt	tgaaattgaa	tttttcaaac	gtttctttgc	ctagcctaata	3000
tttcgaaacc	ccgcttttat	atatgaagcg	gtttttttat	tggtctggaaa	agaacctttc	3060
cgttttcgag	taagatgtga	tcgaaaagga	gagaatgaag	tgaaagtaaa	aaaattagtt	3120
gtggtcagca	tgctgagcag	cattgcattt	gttttgatgc	tgttaaattt	cccgtttccg	3180
ggtcttcctg	attattttaa	aatcgatttt	agcgacgttc	ccgcaattat	tgccattctg	3240
atttacggac	ctttggcggg	atcactagag	ggctcccaac	gcgttggatg	catagcttga	3300
gtattctata	gtgtcaccta	aatagcttgg	cgtaatcatg	gtcatagctg	tttctgtgtg	3360
gaaattgtta	tccgctcaca	attccacaga	acatacagac	cggaagcata	aagtgtaaaag	3420
cctgggggtg	ctaattgagt	agctaactca	cattaattgc	gttgcgctca	ctgcccgctt	3480
tccagtcggg	aaacctgtcg	tgccagctgc	attaatgaat	cggccaacgc	gcggggagag	3540
gcggtttgcg	tattgggcgc	tcttcgctt	cctcgctcac	tgactcgctg	cgctcggtcg	3600
ttcggtctgc	gcgagcggta	tcagctcact	caaaggcggt	aatacggtta	tccacagaat	3660
caggggataa	cgaggaag	aacatgtgag	caaaaggcca	gcaaaaggcc	aggaaccgta	3720
aaaaggccgc	gttgctggcg	tttttcgata	ggctccgccc	ccctgacgag	catcacaaaa	3780
atcgacgctc	aagtcagagg	tggcgaaacc	cgacaggact	ataaagatac	caggcgtttc	3840
cccctggaag	ctccctcggt	cgctctctg	ttccgacct	gccgcttacc	ggatacctgt	3900
ccgcctttct	cccttcggga	agcgtggcgc	tttctcatag	ctcacgctgt	aggtatctca	3960
gttcggtgta	ggtcggtcgc	tccaagctgg	gctgtgtgca	cgaaccccc	gttcagcccc	4020
accgctgcgc	cttatccggt	aactatcgct	ttgagtccaa	cccggtaaga	cacgacttat	4080
cgccactggc	agcagccact	ggtaacagga	ttagcagagc	gaggtatgta	ggcgggtgcta	4140
cagagttctt	gaagtgtgg	cctaactacg	gctacactag	aaggacagta	tttggtatct	4200
gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	tagctcttga	tccggcaaac	4260
aaaccaccgc	tggtagcggg	ggtttttttg	tttgcaagca	gcagattacg	cgcagaaaaa	4320
aaggatctca	agaagatcct	ttgatctttt	ctacggggtc	tgacgctcag	tggaacgaaa	4380
actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	gatcttcacc	tagatccttt	4440
taaattaaaa	atgaagtttt	aatcaatct	aaagtatata	tgagtaaact	tggtctgaca	4500
gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctattt	cgttcatcca	4560
tagttgcctg	actccccgtc	gtgtagataa	ctacgatacg	ggagggctta	ccatctggcc	4620
ccagtgtgc	aatgataccg	cgagaccac	gctcaccggc	tccagattta	tcagcaataa	4680
accagccagc	cggaaaggcc	gagcgcagaa	gtggtcctgc	aactttatcc	gcctccatcc	4740
agtctattaa	ttgttgccgg	gaagctagag	taagtagttc	gccagttaat	agtttgcgca	4800
acgttggttg	cattgctaca	ggcatcggtg	tgtcacgctc	gtcggttggt	atggcttcat	4860
tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgttg	tgcaaaaaag	4920
cggtagctc	cttcggctct	ccgatcggtg	tcagaagtaa	gttggccgca	gtgttatcac	4980
tcagtgttat	ggcagcactg	cataattctc	ttactgtcat	gccatccgta	agatgctttt	5040
ctgtgactgg	tgagtactca	accaagtcac	tctgagaata	ccgcgcccgg	cgaccgagtt	5100
gctcttgccc	ggcgtcaata	cgggataata	gtgtatgaca	tagcagaact	ttaaaagtgc	5160
tcattcattg	aaaacggtct	tcggggcgaa	aactctcaag	gatcttaccg	ctgttgagat	5220
ccagttcgat	gtaacccact	cgtgcaccca	actgatcttc	agcatctttt	actttcacca	5280
gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatgccgc	aaaaaaggga	ataaggcgca	5340

```

cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg 5400
gttattgtct catgagcgga tacatatattg aatgtattta gaaaaataaa caaatagggg 5460
ttccgcgcac atttccccga aaagtgccac ctgtatgcgg tgtgaaatac cgcacagatg 5520
cgtaaggaga aaataccgca tcaggcgaaa ttgtaaacgt taatatattg ttaaaattcg 5580
cgttaaatat ttgttaaatac agctcatttt ttaaccaata ggccgaaatc ggcaaaatcc 5640
cttataaatc aaaagaatag accgagatag ggttgagtgt tgttccagtt tggaacaaga 5700
gtccactatt aaagaacgtg gactccaacg tcaaaggcg aaaaaccgtc tatcaggggc 5760
atggcccact acgtgaacca tcacccaaat caagtttttt gcggtcgagg tgccgtaaaag 5820
ctctaaatcg gaaccctaaa gggagccccc gatttagagc ttgacgggga aagccggcga 5880
acgtggcgag aaaggaaggg aagaaagcga aaggagcgcg cgctagggcg ctggcaagtg 5940
tagcggtcac gctgcgcgta accaccacac ccgcccgcgt taa 5983

```

<210> 31

<211> 7330

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 31

```

ttgcggccgc ttcgaaagct gtaatataaa aaccttcttc aactaacggg gcagggttagt 60
gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120
tcattaggcc tatctgacaa ttcctgaata gagttcataa acaatcctgc atgataacca 180
tcacaaacag aatgatgtac ctgtaaagat agcggtaaata atattgaatt acctttatta 240
atgaattttc ctgctgtaat aatgggtaga aggttaattac tattattatt gatatttaag 300
ttaaaccag taaatgaagt ccatggaata atagaaagag aaaaagcatt ttcagggtata 360
ggtgttttgg gaaacaattt ccccgaaacca ttatatcttc ctacatcaga aaggtataaa 420
tcataaaaact ctttgaagtc attcctttaca ggagtccaaa taccagagaa tgttttagat 480
acaccatcaa aaattgtata aagtggctct aacttatccc aataaccta ctctccgtcg 540
ctattgtaac cagttctaaa agctgtattt gagtttatca cccttgtcac taagaaaata 600
aatgcagggt aaaatttata tccttcttgt tttatgtttc ggtataaaac actaatatca 660
atctctgtgg ttatactaaa agtcgtttgt tggttcaaata aatgattaaa tatctctttt 720
ctcttccaat tgtctaaatc aattttatta aagttcattt gatatgcctc ctaaaatttt 780
atctaaagtg aatttaggag gcttacttgt ctgctttctt cattagaatc aatccttttt 840
taaaagtcaa tattactgta acataaatat atatttttaa aatatccac tttatccaat 900
tttcgtttgt tgaactaatg ggtgctttag ttgaagaata aagaccacat taaaaaatgt 960
ggtcttttgt gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct 1020
tgataataag ggtaactatt gaattcggtta ccaagagttt gtagaaacgc aaaaaggcca 1080
tcgctcagga tggccttctg cttaatttga tgcctggcag tttatggcgg gcgtcctgcc 1140
cgccaccctc cgggccgttg cttecgcaacg ttcaaaccg ctcccggcgg atttgccta 1200
ctcaggagag cggtcaccga caaacaacag ataaaacgaa aggccagtc tttcgactga 1260
gcctttcggt ttatttgatg cctggcagtt cctactctc gcatggggag accccacact 1320
accatcgcg ctacggcggt tcacttctga gttcggcatg gggtcagggt ggaccaccgc 1380
gctactgccg ccaggcaaat tctgttttat cagaccgctt ctgcttctg atttaattctg 1440
tatcaggctg aaaatcttct ctcacccgcc aaaacaggat ccaattatgg cagatcaatg 1500
agcttcacag acacaatatc agggacattt gttagtctt tcacaatttt atcttcaga 1560
tgtctgtcaa aggaaagcat catgatggct tctccgcctt tttccttacg gccaacctgc 1620
atagttgcaa tgttaatatc attatctccg agaatacgtc ctactcggcc gatgacacct 1680
gttgatctct gatgctggat atacaccaag tgaccagtcg gataaaaatc aatattaaat 1740
ccattgatct cgacaattcg ttctccgaaa tgaggaaat acgtagccgt tacagtaaaag 1800
gtgctgcgggt ctctgtcac ttttacgctg atgcagttat cgtatccaga ttcagaagag 1860
gaaatttttt cactgaagct aatgccgcgt tcttttgcca ccccccggc attgacctca 1920
ttaacagtag agtctacgcg cggtttttaa aagcctgaca gaagggcttt tgtaatgaac 1980
gatgtttcaa gtttagcaat tgtgccttca tattgaatgg caacatcctg tactggttct 2040
ttcatgcact gtgatacaag gctgccaatt tttcctgcaa tttgatggta aggcttaatt 2100
ttagcaaat catcttttgt catggcaggc aggttgatag ctgacatgac aggcaggcct 2160
tttgcaact gcagaactt ttctgacact tgggcggcga cattgagctg tgcttctttc 2220
gttgatgctc ccaagtggag agtggcaatg actaatggat gatcaacaag tttgttgtca 2280

```


actggcggtt	cgacttcgaa	aacgtcaagc	gctgctcccc	caacatgcc	gttttccaaa	2340
gcttcgagaa	gtgctgcttc	atcgataatt	ccgcctcgcg	cacagttaat	taagcgaacg	2400
ccttttttcg	tttttgcaat	cgtttcttta	ttcaataagc	cttttgtttc	ttttgttaaa	2460
ggcgtgtgaa	cggtaatgat	atccgcactt	tcaagcactt	cttcaaagt	acggctgttt	2520
acgccgattt	ttttcgctct	ttcttccggt	aagaaaggat	caaaaacgtg	cacagtcata	2580
ccgaacgctc	ctcgacgctg	tgcaatttca	cttccgattc	ggcctaattc	tacaatacca	2640
agcgtttttc	cataaagctc	tgaaccgaca	taagctgtgc	ggttccactc	tctggatttc	2700
actgagatat	tagcctgcg	aatgtgtctc	attaaagaag	agatcattgc	aaatgtatgc	2760
tcagctgtcg	aaatgggtgt	gccgttcgga	gcattgatca	cgattacccc	gtgtttcgta	2820
gcctcatcaa	tatcgatatt	atcgacaccg	acaccggctc	ttccgacaat	ttttaaagaa	2880
gtcattttgt	tgaaaaggct	ttctgttact	tttgtcgcg	ttcgcaccaa	aagagcatca	2940
aaagtatgta	attcatcttc	tgcatctgct	acgttttttt	gaacgatttc	aataaagtct	3000
gattcaataa	gtggctgtaa	accgtcggtg	ctcattttgt	ctgagaccaa	tactcgaaac	3060
atgtttttct	ctcctctaga	gcgtcctgct	gttggttaaga	ttattatacc	acacctgtga	3120
gataaagtca	acaacttttt	gcaaaatttt	tcaggaattt	tagcagaggt	tggtctggat	3180
gtagaacaaa	acatcttttc	gctcttgtgc	tgtaggata	tctttcttgg	aagctaggta	3240
ggcctcgagt	tatggcagtt	ggttaaaagg	aaacaaaaag	accgttttca	cacaaaacgg	3300
tctttttcga	tttcttttta	cagtcacagc	cacttttgca	aaaaccggac	agcttcatgc	3360
cttataactg	ctgtttcggt	cgacgaaaca	tcgttagatt	tcctcctaaa	ttgacaaact	3420
aaatatctga	taatttaaca	tattctcaaa	agagtgtcaa	cgtgtattga	cgcagtaaa	3480
gataaaagta	aagcctaata	aatcaatgat	ctgacagctt	gcaggttaata	tatttaattt	3540
gaagcaattc	tctatacagc	caaccagtta	tcgtttataa	tgtaattaaa	tttcatatga	3600
tcaatcttcg	gggcagggtg	aaattcccta	ccggcggtga	tgagccaatg	gctctaagcc	3660
cgcgagctgt	ctttacagca	ggattcggtg	agattccgga	gccgacagta	cagtctggat	3720
gggagaagat	ggaggttcat	aagcgttttg	aaattgaatt	tttcaaactg	ttctttgcct	3780
agcctaattt	tcgaaacccc	gcttttata	atgaagcgg	ttttttattg	gctggaaaag	3840
aacctttccg	ttttcgagta	agatgtgatc	gaaaaggaga	gaatgaagtg	aaagtaaaaa	3900
aattagttgt	ggtcagcatc	caagcttcgc	gaagcggccg	ccgacgcgag	gctggatggc	3960
cttccccatt	atgattcttc	tcgcttcg	cggcatcg	atgcccgct	tgacggccat	4020
gctgtccagg	caggtagatg	acgaccatca	gggacagctt	caaggatcgc	tcgcgctct	4080
taccagccta	acttcgatca	ctggaccgct	gatcgtcacg	gcgatttatg	ccgcctcg	4140
gagcacatgg	aacgggttg	catggattgt	aggcgccg	ctataccttg	tctgcctccc	4200
cgcggttcgt	cgcggtgcat	ggagccgg	cacctcgacc	tgaatggaag	ccggcgccac	4260
ctcgctaacg	gattcaccac	tccaagaatt	ggagccaatc	aattcttg	gagaactgtg	4320
aatgcgcaaa	ccaacccttg	gcagaacata	tccatcgct	ccgccatctc	cagcagccgc	4380
acgcggcgca	tctcgggcag	cgttgggtcc	tgggccacgg	tgcgcatgat	cgtgctcctg	4440
tcgttgagga	cccggctagg	ctggcggggt	tgcccttactg	gttagcagaa	tgaatcaccg	4500
atacgcgagc	gaacgtgaag	cgactgctgc	tgcaaaacgt	ctgcgacctg	agcaacaaca	4560
tgaatggtct	tcggtttccg	tgtttcgtaa	agtctggaaa	cgcggaagtc	agcgccctgc	4620
accattatgt	tccggatctg	catcgcagga	tgctgctggc	taccctgtgg	aacacctaca	4680
tctgtattaa	cgaagcgctg	gcattgacct	tgagtatttt	ttctctggtc	ccgccgcatc	4740
cataccgcca	gttgtttacc	ctcacaacgt	tccagtaacc	gggcatgttc	atcatcagta	4800
accggtatcg	tgagcatcct	ctctcgtttc	atcggtatca	ttacccccat	gaacagaaat	4860
tcccccttac	acggaggcat	caagtgaaca	aacaggaaaa	aaccgcccct	aacatggccc	4920
gctttatcag	aagccagaca	ttaacgcttc	tggagaaact	caacgagctg	gacgcggatg	4980
aacaggcaga	catctgtgaa	tcgcttcacg	accacgctga	tgagctttac	cgcagctgcc	5040
tcgcgcggtt	cgggtgatgac	ggtgaaaacc	tctgacacat	gcagctccc	gagacgggtca	5100
cagcttgtct	gtaagcggat	gccgggagca	gacaagcccc	tcagggcg	tcagcgggtg	5160
ttggcgggtg	tcggggcgca	gccatgacct	agtcaagtag	cgatagcgga	gtgtatactg	5220
gcttaactat	gcggcatcag	agcagattgt	actgagagtg	caccatatgc	ggtgtgaaat	5280
accgcacaga	tgcgtaagga	gaaaataccg	catcaggcgc	tcttccgctt	cctcgctcac	5340
tgactcgctg	cgctcggtcg	ttcggctg	gcgagcggtg	tcagctcact	caaaggcggt	5400
aatacggtta	tccacagaat	caggggataa	cgcaggaaag	aacatgtgag	caaaaggcca	5460
gcaaaaggcc	aggaaccgta	aaaaggccgc	gttgctggcg	tttttccata	ggctccgccc	5520
ccctgacgag	catcacaata	atcgacgctc	aagtcaagag	tgccgaaacc	cgacaggact	5580
ataaagatac	caggcggttc	cccctggaag	ctccctcg	cgctctcctg	ttccgaccct	5640
gccgcttacc	ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	tttctcatag	5700
ctcacgctgt	aggtatctca	gttcgggtga	ggctcgctgc	tccaagctgg	gctgtgtgca	5760
cgaaccccc	gttcagcccc	accgctgcgc	cttatccggt	aactatcg	ttgagtccaa	5820

cccgttaaga	cacgacttat	cgccactggc	agcagccact	ggtaacagga	ttagcagagc	5880
gaggtatgta	ggcggtgcta	cagagttctt	gaagtgggtg	cctaactacg	gctacactag	5940
aaggacagta	tttggatatct	gcgtctgtct	gaagccagtt	accttcggaa	aaagagttgg	6000
tagctcttga	tccggcaaac	aaaccaccgc	tggtagcggg	ggtttttttg	tttgcaagca	6060
gcagattacg	cgagaaaaaa	aaggatctca	agaagatcct	ttgatctttt	ctacgggggtc	6120
tgacgctcag	tggaaacgaaa	actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	6180
gatcttcacc	tagatccttt	taaattaaaa	atgaagtttt	aaatcaatct	aaagtatata	6240
tgagtaaaat	tggctctgaca	gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	6300
ctgtctattt	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	ctacgataacg	6360
ggagggctta	ccatctggcc	ccagtgtgc	aatgataaccg	cgagaccac	gctcaccggc	6420
tccagattta	tcagcaataa	accagccagc	cggaagggcc	gagcgagaa	gtggctcctgc	6480
aactttatcc	gcctccatcc	agtctattaa	ttgttgccgg	gaagctagag	taagtagttc	6540
gccagttaat	agtttgcgca	acgttggtgc	cattgctgca	ggcatcgtgg	tgtcacgctc	6600
gtcgttttgt	atggcttcat	tcagctccgg	ttccaacga	tcaaggcgag	ttacatgatc	6660
ccccatgttg	tgcaaaaaag	cggtagctc	cttcggtcct	ccgatcgttg	tcagaagtaa	6720
gttggccgca	gtgttatcac	tcattggtat	ggcagcactg	cataattctc	ttactgtcat	6780
gccatccgta	agatgctttt	ctgtgactgg	tgagtactca	accaagtcac	tctgagaata	6840
gtgtatgcgg	cgaccgagtt	gctcttgcct	ggcgtcaata	cgggataata	ccgcgccaca	6900
tagcagaact	ttaaaagtgc	tcattcattgg	aaaacgttct	tcggggcgaa	aactctcaag	6960
gatcttaccg	ctgttgagat	ccagttcgat	gtaaccact	cgtgcacca	actgatcttc	7020
agcatctttt	actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatgccgc	7080
aaaaaaggga	ataagggcga	cacggaaatg	ttgaatactc	atactcttcc	tttttcaata	7140
ttattgaagc	atztatcagg	gttattgtct	catgagcgga	tacatatttg	aatgtattta	7200
gaaaaataaa	caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	ctgacgtcta	7260
agaaaccatt	attatcatga	cattaaccta	taaaaatagg	cgtatcacga	ggccctttcg	7320
tcttcaagaa						7330

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/21336

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12P 13/04; C12N 9/02, 9/10, 9/88, 1/20, 15/00; C07H 21/04

US CL : 435/106, 189, 193, 232, 252.3, 320.1; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/106, 189, 193, 232, 252.3, 320.1; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/21772 A2 (OMNIGENE BIOPRODUCTS) 29 March 2001 (29.03.2001), see entire document.	1-10, 16-22, 29, 36-38, 42-49

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

22 August 2002 (22.08.2002)

Date of mailing of the international search report

13 NOV 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Tekchand Sarda

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/21336

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 11-15, 23-28, 30-35, 39-41
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.